



(86) Date de dépôt PCT/PCT Filing Date: 2003/10/28  
(87) Date publication PCT/PCT Publication Date: 2004/05/13  
(85) Entrée phase nationale/National Entry: 2005/03/10  
(86) N° demande PCT/PCT Application No.: CA 2003/001641  
(87) N° publication PCT/PCT Publication No.: 2004/040012  
(30) Priorité/Priority: 2002/10/29 (60/421,993) US

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> C12Q 1/68  
(71) Demandeur/Applicant:  
BASF PLANT SCIENCE GMBH, DE  
(72) Inventeurs/Inventors:  
CHEUNG, WING Y., CA;  
GAGNON, MARIE-JOSEE, CA;  
LAFOREST, MARTIN, CA;  
LANDRY, BENOIT S., CA  
(74) Agent: SMART & BIGGAR

(54) Titre : COMPOSITIONS ET PROCEDES PERMETTANT D'IDENTIFIER DES PLANTES PRESENTANT UNE  
MEILLEURE TOLERANCE AUX HERBICIDES IMIDAZOLINONES  
(54) Title: COMPOSITIONS AND METHODS FOR IDENTIFYING PLANTS HAVING INCREASED TOLERANCE TO  
IMIDAZOLINONE HERBICIDES

(57) **Abrégé/Abstract:**

The present invention provides compositions and methods for assaying commercially relevant imidazolinone herbicide tolerance conferred by a Brassica napus AHAS1 PM1 mutation and a Brassica napus AHAS3 PM2 mutation in a plant.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number  
**WO 2004/040012 A3**

- (51) International Patent Classification<sup>7</sup>: **C12Q 1/68**
- (21) International Application Number:  
PCT/CA2003/001641
- (22) International Filing Date: 28 October 2003 (28.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/421,993 29 October 2002 (29.10.2002) US
- (71) Applicant (for all designated States except US): **BASF PLANT SCIENCE GMBH** [DE/DE]; Carl-Bosch-Strasse 64, Ludwigshafen, 67056 Rhineland-Pfalz (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CHEUNG, Wing, Y.** [CA/CA]; 4015 Balzac Avenue, Brossard, Quebec J4Z 2H1 (CA). **GAGNON, Marie-Josée** [CA/CA]; 71 Rue Bagg, Montreal, Quebec H2W 1K3 (CA). **LAFOREST, Martin** [CA/CA]; 158 Rimbaud, St-Luc, Quebec J2W 2P4 (CA). **LANDRY, Benoit, S.** [CA/CA]; 134 Allée des Cigales, L-Acadie, Quebec J2Y 1B3 (CA).
- (74) Agents: **SCHWARTZ, David, E.** et al.; Smart & Biggar, P.O. Box 2999, Station D, 900-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6 (CA).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:  
29 July 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR IDENTIFYING PLANTS HAVING INCREASED TOLERANCE TO IMIDAZOLINONE HERBICIDES

(57) Abstract: The present invention provides compositions and methods for assaying commercially relevant imidazolinone herbicide tolerance conferred by a *Brassica napus* AHAS1 PM1 mutation and a *Brassica napus* AHAS3 PM2 mutation in a plant.



WO 2004/040012 A3

## COMPOSITIONS AND METHODS FOR IDENTIFYING PLANTS HAVING INCREASED TOLERANCE TO IMIDAZOLINONE HERBICIDES

### BACKGROUND OF THE INVENTION

#### Field of the Invention

[001] This invention relates generally to compositions and methods for identifying *Brassica* plants having increased tolerance to an imidazolinone herbicide.

#### Background Art

[002] Canola is the seed derived from any of the *Brassica* species *B. napus*, *B. campestris/rapa*, and certain varieties of *B. juncea*. Canola oil is high in monounsaturated fats, moderate in polyunsaturated fats, and low in saturated fats, having the lowest level of saturated fat of any vegetable oil. Thus canola oil is an important dietary option for lowering serum cholesterol in humans. In addition, the protein meal which is the byproduct of canola oil production has a high nutritional content and is used in animal feeds.

[003] Imidazolinone and sulfonyleurea herbicides are widely used in modern agriculture due to their effectiveness at very low application rates and relative non-toxicity in animals. Both of these herbicides act by inhibiting acetohydroxyacid synthase (AHAS; EC 4.1.3.18, also known as acetolactate synthase or ALS), the first enzyme in the synthetic pathway of the branched chain amino acids valine, leucine and isoleucine. Several examples of commercially available imidazolinone herbicides are PURSUIT<sup>®</sup> (imazethapyr), SCEPTER<sup>®</sup> (imazaquin) and ARSENAL<sup>®</sup> (imazapyr). Examples of sulfonyleurea herbicides are chlorsulfuron, metsulfuron methyl, sulfometuron methyl, chlorimuron ethyl, thifensulfuron methyl, tribenuron methyl, bensulfuron methyl, nicosulfuron, ethametsulfuron methyl, rimsulfuron, triflusulfuron methyl, triasulfuron, primisulfuron methyl, cinosulfuron, amidosulfuron, fluzasulfuron, imazosulfuron, pyrazosulfuron ethyl and halosulfuron.

[004] Due to their high effectiveness and low toxicity, imidazolinone herbicides are favored for application to many crops, including canola, by spraying over the top of a wide area of vegetation. The ability to spray an herbicide over the top of a wide range of vegetation decreases the costs associated with plantation establishment and maintenance and

decreases the need for site preparation prior to use of such chemicals. Spraying over the top of a desired tolerant species also results in the ability to achieve maximum yield potential of the desired species due to the absence of competitive species. However, the ability to use such spray-over techniques is dependent upon the presence of imidazolinone resistant species of the desired vegetation in the spray over area. In addition, because residual imidazolinones persist in a sprayed field, a variety of resistant species is advantageous for crop rotation purposes.

[005] Unfortunately, the *Brassica* species which are the source of canola are closely related to a number of broad leaf cruciferous weeds, for example, stinkweed, ball mustard, wormseed mustard, hare's ear mustard, shepherd's purse, common peppergrass, flixweed, and the like. Thus it was necessary to develop *Brassica* cultivars which are tolerant or resistant to the imidazolinone herbicides. Swanson, *et al.* (1989) *Theor. Appl. Genet.* **78**, 525-530 discloses *B. napus* mutants P<sub>1</sub> and P<sub>2</sub>, developed by mutagenesis of microspores of *B. napus* (cv 'Topas'), which demonstrated tolerance to the imidazolinone herbicides PURSUIT<sup>®</sup> and ASSERT<sup>®</sup> at levels approaching ten times the field-recommended rates. The homozygous P<sub>2</sub> mutant produced an AHAS enzyme which was 500 times more tolerant to PURSUIT<sup>®</sup> than wild type enzyme, while the AHAS enzyme from the homozygous P<sub>1</sub> mutant was only slightly more tolerant than the wild type enzyme. In field trials, the P<sub>1</sub>, P<sub>2</sub>, and P<sub>1</sub> x P<sub>2</sub> hybrid withstood ASSERT<sup>®</sup> applications up to 800 g/ha with no loss of yield. The P<sub>1</sub> and P<sub>2</sub> mutations were unlinked and semidominant, and P<sub>1</sub> x P<sub>2</sub> crosses tolerated levels of PURSUIT<sup>®</sup> higher than those tolerated by either homozygous mutant. Imidazolinone-tolerant cultivars of *B. napus* were developed from the P<sub>1</sub> x P<sub>2</sub> mutants and have been sold as CLEARFIELD<sup>®</sup> canola. *See also*, Canadian patent application number 2,340,282; Canadian patent number 1,335,412, and European patent number 284419.

[006] Rutledge, *et al.* (1991) *Mol. Gen. Genet.* **229**, 31-40) discloses the nucleic acid sequence of three of the five genes encoding AHAS isoenzymes in *B. napus*, *AHAS1*, *AHAS2*, and *AHAS3*. Rutledge, *et al.* discusses the mutants of Swanson, *et al.* and predicts that the two alleles that conferred resistance to imidazolinone herbicides correspond to *AHAS1* and *AHAS3*. Hattori *et al.* (1995) *Mol. Gen. Genet.* **246**, 419-425 disclose a mutant allele of *AHAS3* from a mutant *B. napus* cv Topas cell suspension culture line in which a single nucleotide change at codon 557 leading to an amino acid change from tryptophan to leucine confers resistance to sulfonylurea, imidazolinone, and triazolopyrimidine herbicides. Codon 557 of Hattori, *et al.* corresponds to codon 556 of the *AHAS3* sequence disclosed in

Rutledge, *et al.*, *supra*, and to codon 556 of the *AHAS3* sequence set forth as GENBANK accession number gi/17775/emb/Z11526/.

[007] A single nucleotide mutation at codon 173 in a *B. napus* ALS gene, corresponding to *AHAS2* of Rutledge *et al.*, *supra*, leads to a change from Pro to Ser (Wiersma *et al.* (1989) *Mol. Gen. Genet.* **219**, 413-420). The mutant *B. napus* *AHAS2* gene was transformed into tobacco to produce a chlorsulfuron tolerant phenotype.

[008] U.S.Pat.Nos. 6,114,116 and 6,358,686 disclose nucleic acid sequences from *B. napus* and *B. oleracea* containing polymorphisms, none of which appears to correspond to the polymorphism disclosed in Hattori, *et al.*, *supra*.

[009] For commercially relevant *Brassica* cultivars, it is necessary to ensure that each lot of herbicide-resistant seed contains all mutations necessary to confer herbicide tolerance. A method is needed to detect mutations in *Brassica* *AHAS1* and *AHAS3* genes that confer increased imidazolinone tolerance to commercial cultivars.

#### SUMMARY OF THE INVENTION

[010] The present invention describes the location and identity of a single nucleotide polymorphism at position 1937 of the *AHAS1* gene of *B. napus*, the polymorphism being designated as the PM1 mutation. The PM1 mutation confers about 15% of the tolerance to imidazolinone herbicides that is present in CLEARFIELD<sup>®</sup> canola. CLEARFIELD<sup>®</sup> canola also contains a second single nucleotide polymorphism at position 1709 of the *AHAS3* gene of *B. napus*, which corresponds to the tryptophan to leucine substitution described in Hattori *et al.*, *supra*. For the purpose of the present invention, this polymorphism is designated as the PM2 mutation. The PM2 mutation confers about 85% of the tolerance to imidazolinone herbicides exhibited by CLEARFIELD<sup>®</sup> canola. Both the PM1 and PM2 mutations are required to produce a *Brassica* plant with sufficient herbicide tolerance to be commercially relevant, as in CLEARFIELD<sup>®</sup> canola.

[011] Accordingly, the present invention provides methods of identifying a plant having increased tolerance to an imidazolinone herbicide by detecting the presence or absence of the *B. napus* PM1 and PM2 mutations in the plant. One of the advantages of the present invention is that it provides a reliable and quick means to detect plants with commercially relevant imidazolinone tolerance.

[012] In one embodiment, the invention provides a method of assaying a plant for imidazolinone herbicide resistance conferred by the combination of the PM1 mutation of the *B. napus* *AHAS1* gene and the PM2 mutation of the *B. napus* *AHAS3* gene. In this method,

genomic-DNA is isolated from the plant, the presence or absence of the PM1 mutation is determined, and the presence or absence of the PM2 mutation is determined, wherein the presence of the PM1 mutation and the PM2 mutation is indicative of commercially relevant imidazolinone tolerance in the plant.

[013] In another embodiment, the invention provides novel polynucleotide primers useful for detecting the PM1 and PM2 mutations.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[014] Figure 1A shows the nucleic acid and amino acid sequences of *B. napus AHAS1* containing the PM1 mutation (SEQ ID NO:1 and SEQ ID NO:101, respectively).

[015] Figure 1B shows the nucleic acid and amino acid sequences of *B. napus AHAS3* containing the PM2 mutation (SEQ ID NO:2 and SEQ ID NO:102, respectively).

[016] Figure 1C shows the nucleic acid and amino acid sequences of wild type *B. napus* cv. 'Topas' *AHAS1* (SEQ ID NO:3 and SEQ ID NO:103, respectively).

[017] Figure 1D shows the nucleic acid and amino acid sequences of wild type *B. napus AHAS3* Topas cv. (SEQ ID NO:4 and SEQ ID NO:104, respectively).

[018] Figure 1E is a table setting forth the sequences of various oligonucleotides (SEQ ID NOs: 5-88) useful in determining the presence or absence of the PM1 and PM2 mutations in accordance with the invention.

[019] Figure 2 is a schematic representation of one embodiment of the PM1 mutation determination step of a primer extension-based assay of the invention. The coding strand is shown with the amino acid translation of the codons. The wild type plant is denoted as 'Topas' (SEQ ID NOs: 105, 106, 24, 105, 106, and 107, respectively, in order of appearance) and the mutated plant is denoted as 'PM1' (SEQ ID NOs: 108, 109, 24, 108, 109, and 110, respectively, in order of appearance). The mutated nucleotide "A" is underlined on the coding strand. The PM1 extension primer is indicated in bold and is placed at its annealing site on *AHAS1*.

[020] Figure 3 is a schematic representation of one embodiment of the PM2 mutation determination step of a primer extension-based assay of the invention. The coding strand is shown with the amino acid translation of the codons. The wild type plant is denoted as 'Topas' (Seq ID NOs: 111, 112, 66, 111, 112, and 113, respectively, in order of appearance) and the mutated plant is denoted as 'PM2' (SEQ ID NOs: 114, 115, 66, 114, 115, and 116, respectively, in order of appearance). The mutated nucleotide "T" is

underlined on the coding strand. The PM2 extension primer is indicated in bold and is placed at its annealing site on *AHAS3*.

[021] Figure 4 is a table describing the predicted phenotypes of double haploid *B. napus* plants used to validate the method of the invention.

[022] Figure 5 is a table describing the results of the method of the invention in an embodiment employing the ABI PRISM<sup>®</sup> SNP detection system.

[023] Figure 6 is a table describing the results of the method of the invention in an embodiment employing the PYROSEQUENCING<sup>™</sup> detection system.

#### **DETAILED DESCRIPTION OF THE INVENTION**

[024] The present invention provides methods and compositions for identifying plants having increased tolerance to an imidazolinone herbicide by virtue of the presence of the *B. napus* PM1 and PM2 mutations. More particularly, the methods and compositions of the present invention allow identification of *Brassica* seeds and plants having commercially relevant imidazolinone tolerance, such as CLEARFIELD<sup>®</sup> canola. In some embodiments, the methods of the invention employ novel polynucleotide primers including PM1 extension primers and PM2 extension primers.

[025] It is to be understood that as used in the specification and in the claims, "a" or "an" can mean one or more, depending upon the context in which it is used. Thus, for example, reference to "a cell" can mean that at least one cell can be utilized.

[026] For the purposes of the present invention, the level of tolerance to imidazolinone herbicides exhibited by CLEARFIELD<sup>®</sup> canola which contains both the PM1 and PM2 mutations is defined as 100% tolerance, or "commercially relevant imidazolinone tolerance" or "commercial field tolerance". The terms "tolerance" and "resistance" are used interchangeably herein.

[027] "Homologs" are defined herein as two nucleic acids or polypeptides that have similar, or "identical", nucleotide or amino acid sequences, respectively. Homologs include allelic variants, analogs, orthologs and paralogs. As used herein, the term "allelic variant" refers to a nucleotide sequence containing polymorphisms that lead to changes in the amino acid sequences of AHAS proteins and that exist within a natural population (e.g., a plant species or variety). As used herein, the term "analog" refers to two nucleic acids that have the same or similar function, but that have evolved separately in unrelated organisms. The term "orthologs" refers to two nucleic acids from different species, but that have evolved from a common ancestral gene by speciation. Normally, orthologs encode polypeptides

having the same or similar functions. As also used herein, the term “paralogs” refers to two nucleic acids that are related by duplication within a genome. Paralogs usually have different functions, but these functions may be related (Tatusov, R.L. *et al.*, 1997. *Science* 278(5338):631-637).

[028] As defined herein, a “PM1 mutation” refers to a single nucleotide polymorphism in a *B. napus AHAS1* gene in which there is a “G” to “A” nucleotide substitution at position 1937 of the *AHAS1* wildtype polynucleotide sequence shown in Figure 1C (SEQ ID NO:3) or at a nucleotide position that corresponds to position 1937 in an *AHAS1* homolog, which substitution leads to a serine to asparagine amino acid substitution at position 638 in the *B. napus AHAS1* enzyme.

[029] A “PM1 oligonucleotide” refers to an oligonucleotide sequence corresponding to a PM1 mutation. An oligonucleotide as defined herein is a nucleic acid comprising from about 8 to about 25 covalently linked nucleotides. In accordance with the invention, an oligonucleotide may comprise any nucleic acid, including, without limitation, phosphorothioates, phosphoramidates, peptide nucleic acids, and the like. As defined herein, “corresponding to a PM1 mutation” includes the following: an oligonucleotide capable of specific hybridization to a region of an *AHAS1* gene which is 5' of position 1937 of the *AHAS1* gene as set forth in SEQ ID NO:3 (for example, an oligonucleotide comprising any one of SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO: 13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO: 19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; or SEQ ID NO:23 as set forth in Figure 1E); an oligonucleotide capable of specific hybridization to a region of an *AHAS1* gene which is 3' of position 1937 of the *AHAS1* gene as set forth in SEQ ID NO:3 (for example, an oligonucleotide comprising any one of SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO: 28; SEQ ID NO:29; SEQ ID No;30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:41; or SEQ ID NO:42 as set forth in Figure 1E); an oligonucleotide capable of specific hybridization to a region of the *AHAS1* gene which spans position 1937 of the *AHAS1* gene as set forth in SEQ ID NO:3 (for example, an oligonucleotide comprising SEQ ID NO: 45 as set forth in Figure 1E); an oligonucleotide capable of specific hybridization to a region of an *AHAS1* gene which is 5' of position 1937 of the complement of the *AHAS1* gene set forth in SEQ ID NO:3; an oligonucleotide capable of specific hybridization to a region of an *AHAS1* gene which is 3' of position 1937 of the



complement of the *AHAS1* gene set forth in SEQ ID NO:3; and an oligonucleotide capable of specific hybridization to a region of the *AHAS1* gene which spans position 1937 of the complement of the *AHAS1* gene as set forth in SEQ ID NO:3 (for example, an oligonucleotide comprising SEQ ID NO: 46 as set forth in Figure 1E). The term "nucleic acid" includes RNA or DNA that is linear or branched, single or double stranded, or a hybrid thereof. These terms also encompass RNA/DNA hybrids.

[030] As defined herein, a "PM2 mutation" refers to a single nucleotide polymorphism in a *B. napus AHAS3* gene in which there is a "G" to "T" nucleotide substitution at position 1709 of the *AHAS3* wildtype polynucleotide sequence shown in Figure 1D (SEQ ID NO:4) or at a nucleotide position that corresponds to position 1709 in an *AHAS3* homolog, which substitution leads to a tryptophan to leucine amino acid substitution at position 556 in the *B. napus AHAS3* enzyme.

[031] A "PM2 oligonucleotide" refers to an oligonucleotide sequence corresponding to a PM2 mutation. As defined herein, "corresponding to a PM2 mutation" includes the following: an oligonucleotide capable of specific hybridization to a region of an *AHAS3* gene which is 5' of position 1709 of the *AHAS3* gene as set forth in SEQ ID NO:4 (for example, an oligonucleotide comprising any one of SEQ ID NO:47; SEQ ID NO:48; SEQ ID NO:49; SEQ ID NO:50; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:53; SEQ ID NO:54; SEQ ID NO:55; SEQ ID NO:56; SEQ ID NO:57; SEQ ID NO:58; SEQ ID NO:59; SEQ ID NO:60; SEQ ID NO:61; SEQ ID NO:62; SEQ ID NO:63; SEQ ID NO:64; or SEQ ID NO:65 as set forth in Figure 1E); an oligonucleotide capable of specific hybridization to a region of an *AHAS3* gene which is 3' of position 1709 of the *AHAS3* gene as set forth in SEQ ID NO:4 (for example, an oligonucleotide comprising any one of SEQ ID NO:66; SEQ ID NO:67; SEQ ID NO:68; SEQ ID NO:69; SEQ ID NO:70; SEQ ID NO:71; SEQ ID NO:72; SEQ ID NO:73; SEQ ID NO:74; SEQ ID NO:75; SEQ ID NO:76; SEQ ID NO:77; SEQ ID NO:78; SEQ ID NO:79; SEQ ID NO:80; SEQ ID NO:81; SEQ ID NO:82; SEQ ID NO:83; and SEQ ID NO:84 as set forth in Figure 1E); an oligonucleotide capable of specific hybridization to a region of the *AHAS3* gene which spans position 1709 of the *AHAS3* gene as set forth in SEQ ID NO:4 (for example, an oligonucleotide comprising SEQ ID NO: 85 as set forth in Figure 1E); an oligonucleotide capable of specific hybridization to a region of an *AHAS3* gene which is 5' of position 1709 of the complement of the *AHAS3* gene set forth in SEQ ID NO:4; an oligonucleotide capable of specific hybridization to a region of an *AHAS3* gene which is 3' of position 1709 of the complement of the *AHAS3* gene set forth in SEQ ID NO:4; and an oligonucleotide capable of specific hybridization to a region of the *AHAS3*

gene which spans position 1709 of the complement of the *AHAS3* gene as set forth in SEQ ID NO:4 (for example, an oligonucleotide comprising SEQ ID NO: 86 as set forth in Figure 1E).

[032] Also encompassed in the present invention are oligonucleotides corresponding to the wild type alleles at the PM1 and PM2 mutations which are useful as controls in the SNP detection assays. For example, an oligonucleotide corresponding to position 1937 of the *AHAS1* gene set forth in SEQ ID NO:1, comprising a sequence selected from the group consisting of SEQ ID NO:43 and SEQ ID NO:44 as set forth in Figure 1E, is useful as a control in a SNP assay for the PM1 mutation. Similarly, an oligonucleotide corresponding to position 1709 of the *AHAS3* gene set forth in SEQ ID NO:2, comprising a sequence selected from the group consisting of SEQ ID NO:85 and SEQ ID NO:86 as set forth in Figure 1E, is useful as a control in a SNP assay for the PM2 mutation.

[033] The presence of the PM1 and PM2 mutations in a plant may confer tolerance to such imidazolinone herbicides as PURSUIT<sup>®</sup> (imazethapyr, 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-5-ethyl-3-pyridinecarboxylic acid), CADRE<sup>®</sup> (imazapic, 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-5-methyl-3-pyridinecarboxylic acid), RAPTOR<sup>®</sup> (imazamox, 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-5-(methoxymethyl)-3-pyridinecarboxylic acid), SCEPTER<sup>®</sup> (imazaquin, 2-(4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl)-3-quinolinecarboxylic acid), ASSERT<sup>®</sup> (imazethabenz, methyl esters of 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-4-methylbenzoic acid and 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-5-methylbenzoic acid), ARSENAL<sup>®</sup> (imazapyr, 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-3-pyridinecarboxylic acid), and the like. In addition, the PM1 and PM2 mutations may confer resistance to sulfonylurea and triazolopyrimidine herbicides.

[034] The PM1 and PM2 mutations may be present in a plant by virtue of mutagenesis of any species of plant containing the *B. napus AHAS1* and *AHAS3* genes, respectively. Alternatively, the PM1 and PM2 mutations may be present in a plant by virtue of transformation of the *B. napus AHAS1* PM1 gene and the *B. napus AHAS3* PM2 genes into the plant, using known methods such as those set forth in U.S.Pat.Nos. 5,591,616; 5,767,368; 5,736,369; 6,020,539; 6,153,813; 5,036,006; 5,120,657; 5,969,213; 6,288,312; 6,258,999, and the like. Preferably, the plant is a *Brassica* oilseed. More preferably, the plant species is selected from the group consisting of *B. napus*, *B. campestris/rapa*, and *B. juncea*. Most

preferably, the plant species is *B. napus*. In accordance with the present invention, the term "plant" includes seeds, leaves, stems, whole plants, organelles, cells, and tissues.

[035] In the first step of the method of the invention, genomic DNA is isolated from the plant. It is to be understood that when practicing the method of the present invention, genomic DNA can be extracted from the plant by any method known to those of skill in the art. Genomic DNA can be extracted from a whole plant, a plant leaf, a plant stem, a plant seed, or any plant organelle, cell or tissue. One non-limiting method for extracting the DNA from a plant leaf is described in Example 1 below.

[036] In the second step of the method of the invention, the presence or absence of the PM1 mutation in the extracted DNA is determined. In the third step of the invention, the presence or absence of the PM2 mutation in the extracted DNA is determined. In accordance with the invention, the steps of detecting the PM1 and PM2 mutations may be performed in any order, or simultaneously.

[037] Any method may be used to detect the PM1 and PM2 mutations. For example, commercially available single nucleotide polymorphism (SNP) detection systems may be used, such as the SNP-IT™ system (Orchid Biosciences, Princeton, NJ), the MassArray™ System (Sequenom, Inc., San Diego, CA), the BeadArray™ System (Illumina, San Diego, CA), the ABIPrism Genetic Analyzer (Applied Biosystems, Foster City, CA), the ALFexpress™ (Amersham Biosciences, Buckinghamshire, UK), the PSQ™96 System (Pyrosequencing AB, Uppsala, Sweden), the Invader™ assay (Third Wave Agbio, Inc., Madison, WI), and the like. A variety of methods exist for identification of a nucleotide at a polymorphic site in a nucleic acid, as described, for example, in U.S.Pat.Nos. 6,087,095; 6,046,005; 6,017,702; 5,981,186; 5,976,802; 5,928,906; 5,912,118; 5,908,755; 5,869,242; 5,853,979; 5,849,542; 5,834,189; 4,851,331; 4,656,127; 5,679,524; 6,004,744; 6,013,431; 6,210,891; 6,183,958; 5,958,692; 5,851,770; 6,110,684; 5,856,092; 5,605,798; 5,547,835; 6,194,144; 6,043,031; 6,322,980; 6,340,566, and the like. Such technologies include, but are not limited to, allele-specific primer extension, allele-specific hybridization, allele-specific ligation, allele-specific enzymatic cleavage, mismatch detection using resolvase, and sequencing. These technologies can be combined with different signal detection technologies such as fluorescence, fluorescence resonance energy transfer, fluorescence polarization, luminescence and mass spectroscopy.

[038] In some embodiments of the method of the invention, the isolated DNA is combined with a PM1 extension primer and a PM2 extension primer, as defined below, in the presence of one or more SNP detection reagents, thereby creating a detection product. The

detection product is then examined to determine the presence or absence of a PM1 mutation or a PM2 mutation in the isolated DNA. As used herein, the term "SNP detection reagent" refers to any reagent that is part of any SNP technology, technique or kit that can be used to detect single nucleotide polymorphisms.

[039] In one embodiment, the template DNA is combined with a first extension primer which is suitable for detection of a PM1 mutation, a second extension primer suitable for detection of a PM2 mutation, and one or more SNP detection reagents. An "extension primer" is an oligonucleotide that binds to the target DNA upstream from the target mutation in the direction of extension. In accordance with the invention, a PM1 extension primer comprises an oligonucleotide corresponding to a PM1 mutation. Similarly, a PM2 extension primer comprises an oligonucleotide corresponding to a PM2 mutation. The extension primer will preferably have a length from about 12 nucleotides to about 100 nucleotides, and more preferably have a length from about 18 nucleotides to about 60 nucleotides.

[040] The extension primer may be chosen to bind substantially uniquely to a target sequence containing a PM1 or PM2 mutation under the conditions of primer extension, so that the sequence will normally be one that is conserved or the primer is long enough to bind in the presence of a few mismatches, usually fewer than about 10% mismatches. By knowing the sequence that is upstream from the PM1 or PM2 mutation, one can select a sequence that has a high G-C ratio, so as to have a high binding affinity for the target sequence. In addition, the extension primer should bind reasonably close to the PM1 or PM2 mutation, preferably not more than about 200 nucleotides away, more preferably not more than about 100 nucleotide away, and most preferably within 50 nucleotides. In a preferred embodiment, the extension primer binds between 1 and 5 nucleotides away from the PM1 or PM2 mutation.

[041] Both the PM1 extension primer and the PM2 extension primer described herein are preferred extension primers. In one embodiment of the present invention, the PM1 extension primer comprises a sequence as shown in SEQ ID NO:24, or any contiguous primer, noncontiguous primer or homologous primer thereof. In another or further embodiment of the present invention, the PM2 extension primer comprises a sequence as shown in SEQ ID NO:66, or any contiguous primer, noncontiguous primer or homologous primer thereof. The PM1 or PM2 primer can also comprise an RNA version of any of the aforementioned extension primers.

[042] The term "contiguous primer" refers to a polynucleotide sequence that contains at least a fragment of the polynucleotide sequence of SEQ ID NO:24, SEQ ID

NO:66, SEQ ID NO:23 or SEQ ID NO:65. In one embodiment, the contiguous primer contains a 5' or 3' fragment of SEQ ID NO:24, SEQ ID NO:66, SEQ ID NO:23 or SEQ ID NO:65 in addition to one or more nucleotides complementary to upstream or downstream PM1 or PM2 polynucleotide sequences. For example, a contiguous primer of the PM1 primer shown in SEQ ID NO:24 could comprise a nucleotide sequence of TAC ATCTTTGAAAGTGCCA (SEQ ID NO:89). The term "noncontiguous primer" refers to a sequence that is not contiguous with a PM1 or PM2 primer (i.e., a contiguous fragment of the PM1 or PM2 primer), but which sequence contains portions of a PM1 or PM2 primer sequence sufficient to provide the amplification or detection results obtained with SEQ ID NO:24, SEQ ID NO:66, SEQ ID NO:23 or SEQ ID NO:65. For example, with reference to Figure 1E, oligonucleotides having SEQ ID NOs: 5-21 are noncontiguous with the PM1 primer having SEQ ID NO:23. Finally, the term "homologous primer" refers to a polynucleotide sequence that is substantially homologous with SEQ ID NO:24, SEQ ID NO:66, SEQ ID NO:23 or SEQ ID NO:65 or a contiguous primer thereof. In a preferred embodiment, the contiguous, non-contiguous or homologous primer has the attributes of an extension primer as described above, and more preferably, binds immediately upstream or downstream from a PM1 or PM2 mutation.

**[043]** Substantially homologous primers included in the present invention are those that provide detection results in ranges similar to those obtained with the oligonucleotide sequence shown in SEQ ID NO:24, SEQ ID NO:66, SEQ ID NO:23 or SEQ ID NO:65. In a preferred embodiment, a primer substantially homologous to SEQ ID NO:24, SEQ ID NO:66, SEQ ID NO:23 or SEQ ID NO:65 is at least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-75%, 75-80%, 80-85%, 85-90% or 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more identical to an entire oligonucleotide sequence shown in SEQ ID NO:24, SEQ ID NO:66, SEQ ID NO:23 or SEQ ID NO:65.

**[044]** To determine the percent sequence identity of two polynucleotide sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one polynucleotide for optimal alignment with the other polynucleotide). The polynucleotides at corresponding positions are then compared. When a position in one sequence (e.g., a sequence of SEQ ID NO:24, SEQ ID NO:66, SEQ ID NO:23 or SEQ ID NO:65) is occupied by the same nucleotide as the corresponding position in the other sequence, then the molecules are identical at that position. Accordingly, the percent sequence identity between the two sequences is a function of the number of identical

positions shared by the sequences (i.e., percent sequence identity = numbers of identical positions/total numbers of positions x 100). For the purposes of the invention, the percent sequence identity between two nucleic acid or polypeptide sequences is determined using the Vector NTI 6.0 (PC) software package (InforMax, 7600 Wisconsin Ave., Bethesda, MD 20814). A gap opening penalty of 15 and a gap extension penalty of 6.66 are used for determining the percent identity of two nucleic acids. A gap opening penalty of 10 and a gap extension penalty of 0.1 are used for determining the percent identity of two polypeptides. All other parameters are set at the default settings. It is to be understood that for the purposes of determining sequence identity when comparing a DNA sequence to an RNA sequence, a thymidine nucleotide is equivalent to a uracil nucleotide.

[045] The methods described in the examples employ the coding sequences of the PM1 and PM2 mutations as templates, but the method works equally well with SNP detection assays using the non-coding sequence and the primers. For example, a PM1 extension primer with the non-coding strand as template (5'TGTGTTACCGATGATCCCAA<sup>3'</sup>; SEQ ID NO:23) and a PM2 extension primer with a non-coding strand as template (5'TCTTGGGATGGTCATGCAAT<sup>3'</sup>; SEQ ID NO:65) may be used with the ABIPrism SnaPshot assay available from Applied Biosystems (Foster City, CA).

[046] Prior to the detection steps, template DNA containing the PM1 and PM2 mutations may optionally be amplified using known methods. Amplification and creation of a DNA template can be achieved using any method known to those of skill in the art including PCR. The term "PCR" as used herein refers to the polymerase chain reaction method of DNA amplification. As will be understood by one of ordinary skill in the art, this term also includes any and all other methods known in the art for nucleic acid amplification requiring an amplification target, at least one primer and a polymerase.

[047] For example, either PM1 template DNA or PM2 template DNA may be amplified by combining the isolated genomic DNA with an appropriate primer set for the amplification of a polynucleotide sequence containing a PM1 or PM2 mutation. Each primer set consists of a forward primer and a reverse primer, each of which can be referred to as an "amplification primer." In one embodiment of the present invention, *AHAS1* and *AHAS3* template DNAs may be amplified using a single primer set wherein a first amplification primer comprises the sequence 5' GGC GTT TGG TGT TAG GTT TGA 3' (SEQ ID NO:90) and a second amplification primer comprises the sequence 5' CGT CTG GGA ACA ACC AAA AGT 3' (SEQ ID NO:91). Alternatively, an *AHAS1* template DNA may be separately

amplified using an *AHAS1*-specific forward primer 5' GGA AAG CTC GAG GCT TTC GCT 3' (SEQ ID NO: 92) and an *AHAS1/AHAS3* reverse primer 5' ATC ACC AGC TTC ATC TCT CAG T 3' (SEQ ID NO: 93). In this embodiment, an *AHAS3* template DNA may be separately amplified using an *AHAS3*-specific forward primer (5' GGA AAG CTC GAG GCG TTT GCG 3'; SEQ ID NO: 94) and the *AHAS1/AHAS3* reverse primer (5' ATC ACC AGC TTC ATC TCT CAG T 3'; SEQ ID NO: 93).

[048] Those of ordinary skill will recognize that additional amplification primers may be prepared which are contiguous, noncontiguous or homologous primer to the amplification primers et forth above. The forward and reverse primers can also be an RNA version of any of the aforementioned amplification primers.

[049] The invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof.

## EXAMPLES

### Example 1

#### *Isolation of genomic DNA from a Plant*

[050] The DNA extraction procedure described below (Cheung *et al.*, 1993 PCR Methods and Applications 3:69-70) can be used for both fresh and lyophilized leaf tissues. If fresh leaf tissues are used, the Phenol and chloroform/isoamyl-alcohol extraction steps can be omitted.

[051] Two 5 mm diameter leaf discs made with a paper punch or the equivalent were taken from each leaf sample and immediately placed in 320 µl of sterile extraction buffer containing 200 mM Tris-HCl (pH 8.0), 70 mM EDTA, 2 M NaCl and 20 mM sodium metabisulfite. Leaves were then ground until no visible pieces of tissue remained. Cells were lysed with addition of 80 µl of 5% sodium sarcosyl to each tube and were incubated at 60 °C for an hour. After 15 minutes of centrifugation at 13,800 RPM, the supernatant was transferred to a fresh tube and an equal volume of buffer saturated phenol was added. The contents in the tubes were mixed by inverting a few times and were spun at 13,800 RPM for 5 minutes.

[052] The aqueous phase was then transferred into a fresh tube and an equal volume of chloroform/isoamyl alcohol (24:1 v/v) was added and mixed by inverting tubes a few times and then was spun at 13,800 RPM for 5 minutes. After transferring the aqueous phase to a fresh tube, 180 µl of filter-sterilized 10 M ammonium acetate and 400 µl of isopropanol were

then added and left at room temperature for 15 minutes for DNA precipitation. After centrifuging for 15 minutes at 13,800 RPM, the supernatant was removed the pellets were rinsed once in 70% EtOH and left to air dry. The DNA pellet was resuspended in 100 µl TE buffer with 0.01 mg/ml of RNase and a 9 µl aliquot of DNA was run on 0.8% agarose to check for quantity and quality.

## Example 2

### *DNA Amplification and Clean-Up*

[053] Preliminary testing showed that the primer pair, Primer 1 (5' GGC GTT TGG TGT TAG GTT TGA 3') (SEQ ID NO:90) and Primer 2 (5' CGT CTG GGA ACA ACC AAA AGT 3') (SEQ ID NO:91) could amplify in one PCR reaction sufficient amounts of both *AHAS1* and *AHAS3* sequences for both PM1 and PM2 tests. Each PCR reaction mixture was set up in a total volume of 75 µl containing 1X PCR buffer II (Perkin Elmer), 2.5 mM MgCl<sub>2</sub>, 200 µM of each dNTP, 400 nM each of Primer 1 and Primer 2, 100 ng of DNA (or 4 µl of extracted DNA) and 3 units of AmpliTaq<sup>®</sup> DNA polymerase (Perkin Elmer). Amplification reactions were carried out in Perkin Elmer GeneAmp 9600 or 9700 PCR systems. The PCR program included an initial denaturing step at 94 °C, followed by 30 cycles of denaturation at 94 °C for 10 seconds, annealing at 56 °C for 15 seconds, and extension at 72 °C for 30 seconds with a final extension step of 5 minutes at 72 °C. An aliquot of the PCR product was checked on 1.4 % agarose for an expected product size of 1Kb.

[054] In the clean-up step, 50 µl of each PCR product was first treated with 10 units of CIP (calf intestinal phosphatase, NEW ENGLAND BioLabs Inc.) by incubating at 37 °C for 1 hour and then deactivating the enzyme by incubating at 72 °C for 15 minutes in Perkin Elmer GeneAmp 9700 PCR systems. Subsequently, the 50 µl aliquot was purified using the QIAquick<sup>™</sup> 96 PCR Purification Kit (QIAGEN) and eluted in 50 µl ddH<sub>2</sub>O. Samples were then placed in a Universal Vacuum System UVS400/Speed Vac<sup>®</sup> Plus SC110A (Savant) for approximately 1 hour or until the water in the sample completely evaporated. The CIP treated and purified PCR product was resuspended in ddH<sub>2</sub>O at a concentration of approximately 50 ng/µl and was used as DNA templates for the primer extension reactions for detecting the PM1 and PM2 mutations.



### Example 3

#### *Primer Extension PCR for Detecting PM1 and PM2 Mutations using ABI PRISM<sup>®</sup>*

[055] The ABI PRISM<sup>®</sup> SNaPshot ddNTP Primer Extension Kit was used on each DNA sample and to detect both the PM1 and the PM2 single nucleotide mutations. The mutation detecting primers are as follows: PM1 extension primer: 5' CAT CTT TGA AAG TGC CAC CA 3' (SEQ ID NO:24) for detection of the PM1 mutation and PM2 extension primer: 5' CTT TGT AGA ACC GAT CTT CC 3' (SEQ ID NO:66) for detection of the PM2 mutation. Primer extension reactions were performed with 100 ng of CIP treated and purified PCR amplified templates in a total volume of 10 µl with 100 nM of the appropriate mutation primer, SNaPshot Ready Reaction Premix as indicated by the manufacturer. Thermal cycling was performed in Perkin Elmer GeneAmp 9600 or 9700 PCR systems with conditions set for 25 cycles of denaturation at 96 °C for 10 seconds, annealing at 50 °C for 5 seconds and extension at 60 °C for 30 seconds. Post-extension treatment consisted of incubating the reaction mixture for 1 hour at 37 °C with 1 unit of calf intestinal phosphatase (NEW ENGLAND BioLabs Inc.) and the enzyme was inactivated at 72 °C for 15 minutes. Samples were then prepared for loading on an ABI PRISM<sup>®</sup> 3700 DNA Analyzer by adding 1µl of each post-extension treated reaction to 10 µl of deionized formamide, denatured at 95 °C for 5 minutes and then loaded and run using a GeneScan 5 Run Module. Data was collected and viewed using the ABI PRISM<sup>®</sup> GeneScan v. 3.5.1 software.

### Example 4

#### *Detection of PM1 and PM2 Mutations in B. napus using ABI PRISM<sup>®</sup>*

[056] The PM1 test using the primer PM1 involves the extension of the next nucleotide to the primer sequence with the coding strand as the template. Thus, in the wildtype plant, here a *B. napus* cv. 'Topas' plant, the observed nucleotide should be "C" corresponding to the wildtype "G" in the codon "AGT" for Serine on the coding strand. When the test is done on the mutated PM1 *B. napus* plant, the observed nucleotide should be "T" corresponding to the mutated "A" in the codon "AAT" for Asparagine on the coding strand (Figure 2). The results obtained with the ABI PRISM<sup>®</sup> method showed exactly the predicted results. A mutated PM2 *B. napus* plant that did not contain the PM1 mutation was shown to provide the same results as the wildtype 'Topas' plant in the PM1 test. Therefore, the PM1 mutation was detected accurately in *B. napus* using the ABI PRISM<sup>®</sup> primer extension methodology.

[057] Similarly, the PM2 test using the primer PM2 involves the extension of the next nucleotide to the primer sequence with the coding strand as the template. Thus, in the wildtype plant, e.g. 'Topas', the observed nucleotide should be "C" corresponding to the wildtype "G" in the codon "TGG" for Tryptophan on the coding strand. When the test was done on the mutated PM2 *B. napus* plant, the observed nucleotide should be "A" corresponding to the mutated "T" in the codon "TTG" for Leucine on the coding strand (Figure 3). The results obtained with the present method showed exactly the predicted results. A mutated PM1 *B. napus* plant that does not have the PM2 mutation was shown to provide the same results as the wildtype 'Topas' plant in the PM2 test. Therefore, the PM2 mutation was detected accurately in *B. napus* using the ABI PRISM<sup>®</sup> primer extension methodology.

### Example 5

#### *Validation of ABI PRISM<sup>®</sup> PM1 and PM2 Detection Method*

[058] In order to validate the use of the present method on plant materials with a genetic background different from the one used to develop the markers and the method (the *B. napus* 'Topas' plant), the PM1 and PM2 tests were performed to detect the presence or absence of the CLEARFIELD<sup>®</sup> trait on 24 doubled haploid (DH) (*i.e.*, homozygous) canola lines. These 24 lines were divided into four classes: PM1, PM2, PM1/PM2 and WT based on the results of survival after spraying with herbicide. The codes and classification of the DH lines are summarized in Figure 4, in which "GH Rating" means greenhouse rating on mortality: 0 means all plants survive after spraying and 85% means 85% of the plants died after spraying. Also included in Figure 4 are the three controls used in the validation tests: PM1, PM2 and WT, all from the *B. napus* 'Topas' var. used in Examples 2 through 4 for development of the PM1/PM2 assay. The amplification of the templates and the mutation tests were repeated three times for each DH line from Advanta Seeds and twice for the three control samples.

[059] The results of the PM1 and PM2 mutation tests are summarized in Figure 5. The plant number in Figure 5 corresponds to the plant number in Figure 4. Additionally, the peaks related to the mutations are in bold and in italics while the peaks that are not always present or present in various amounts in all the three replicates are in brackets. The "Expected Results" column reflects those results that are expected assuming that the amplification reaction using the primer pair *AHAS1/AHAS3* amplification primer of SEQ ID NO: 90 and the *AHAS1/AHAS3* amplification primer of SEQ ID NO: 91 amplified similar

amounts of both *AHAS1* and *AHAS3* sequences and that the PM1 extension primers will anneal also to the *AHAS3* sequence and the PM2 extension primers will anneal also to the *AHAS1* sequence.

[060] As shown in Figure 5, the observed results for both the PM1 and PM2 mutation tests agreed with the expected results for all six plants in the PM1/PM2 class. With the PM1 class, all six plants showed the PM1 mutation (as "T"). All of the wild-type plants showed the absence of either mutation. Therefore, with all three classes of plants, the present invention can correctly predict the presence or absence of the PM1 and PM2 mutations.

[061] The results for the PM2 class were more complicated. All the six plants of the PM2 classes were expected to have the PM2 mutation (i.e. an "A" with the PM2 mutation test). In fact, all the six plants did detect an "A" with the test throughout the three replicates. The PM2 class was expected to have the wild-type "C" for the PM1 mutation test. However, in the observed results, only plant #40 showed the wild-type "C", while each of the other five plants consistently showed a "T" for the PM1 mutation test, indicating the unexpected presence of the of the PM1 mutation . The control lines gave the expected results.

[062] It is believed that the discrepancy in the expected and actual results regarding the plants classified as containing only the PM2 mutation is due to misclassification under the herbicide spraying test and that this discrepancy reflects the superiority of the present invention. One advantage of using the present invention to identify the presence or the absence of PM1 or PM2 mutations over the herbicide spraying test is that the present invention can unequivocally tell whether the mutations are present in the genetic materials of the tested plants. Hence, the invention described herein presents a more reliable test which will not be influenced by other environmental factors.

[063] Using the present invention, one can easily tell apart the wild type plants from those with only the PM1 mutation and also differentiate between plants with only PM1 or PM2 mutations and those with both PM1 and PM2 mutations, which are particularly difficult to distinguish using the spraying test. With the prior art herbicide spraying test, a statistical number of plants of the same line need to be grown and sprayed to obtain meaningful results while with the present invention, fewer plants from the same line need to be tested. Since the methods of the present invention only require very small amount of leaf materials per line, another advantage of these methods is that they can be performed when the plants are very young, for example at the cotyledon stage. This advantage translates into savings in growth space and other costs.

### Example 6

#### *Detection of PM1 and PM2 Mutations in B. napus using PYROSEQUENCING PSQ™ 96*

[064] A second method to allow high throughput detection of the presence or absence of "PM1" and "PM2" mutations in *B. napus* was designed, the method comprising four steps:

1. Isolation of genomic DNA
2. Separation of *AHAS1* and *AHAS3* DNA template preparations by PCR with an *AHAS1*-specific forward primer paired with a biotinylated *AHAS1/AHAS3* reverse primer for *AHAS1* and an *AHAS3*-specific forward oligonucleotide primer paired with the same biotinylated *AHAS1/AHAS3* reverse primer for *AHAS3*
3. Isolation of single stranded DNA templates
4. PYROSEQUENCING™ reactions with PM1 sequencing primer for detecting the "PM1" mutation and PM2 sequencing primer for detecting the "PM2" mutations.

#### *DNA Isolation*

[065] The procedure set forth in Example 1 was used to isolate DNA from plants for analysis using the PYROSEQUENCING™ method.

#### *DNA amplification*

[066] For detection of the PM1 and PM2 mutations using the PYROSEQUENCING™ method, the best results were obtained when *AHAS1* and *AHAS3* sequences were separately amplified as templates. Therefore, two amplification reactions were first performed using different forward primers, *AHAS1*-specific forward primer for *AHAS1* (5' GGA AAG CTC GAG GCT TTC GCT 3'; SEQ ID NO:92) and *AHAS3*-specific forward primer for *ALSS3* (5' GGA AAG CTC GAG GCG TTT GCG 3'; SEQ ID NO: 94) but pairing with the same biotinylated reverse primer, *AHAS1/AHAS3* reverse primer (5' ATC ACC AGC TTC ATC TCT CAG T 3'; SEQ ID NO:93). Each PCR reaction was set up in a total volume of 30 µl containing 1X PCR buffer II (Applied Biosystems, Foster City, CA), 2.5 mM MgCl<sub>2</sub>, 200 µM of each dNTP, 300 nM each of an *AHAS1*-specific forward primer and *AHAS1/AHAS3* reverse primer for *AHAS1* and an *AHAS3*-specific forward primer and *AHAS1/AHAS3* reverse primer for *AHAS3*, 5 ng of DNA and 1.25 units of AmpliTaq® Gold DNA polymerase (Applied Biosystems, Foster City, CA). Amplification reactions were carried out in Applied Biosystems GeneAmp 9600® or GeneAmp 9700® PCR systems. The PCR program includes an initial denaturing step at 94°C for 10 minutes, followed by 45 cycles of denaturation at 94°C for 10 seconds, annealing at 56°C for 15 seconds, and

extension at 72°C for 30 seconds with a final extension step of 10 minutes at 72°C. An aliquot of each PCR product was checked on 1% agarose for an expected product size of 1Kb.

*Single strand template isolation and annealing of sequencing primers for detection of "PM1" and "PM2" mutations*

**[067]** PCR amplified products were immobilized by mixing 25 µl of the PCR product with 150 ng of Dynabeads<sup>®</sup> M-280 Streptavidin (Dynal AS, Oslo, Norway) and 25 µl of 2X Binding-Washing buffer II pH 7.6 (PYROSEQUENCING<sup>™</sup>) and were incubated on an agitator at 65° for 30 minutes. Using the PSQ 96 Sample Prep Tool, the beads carrying the biotinylated templates were then transferred and released into a PSQ 96 Plate containing 50 µl of 0.5 M NaOH per well and left to soak with gentle agitation for 1 minute. The beads now carrying the isolated biotinylated non-coding strands were then transferred into a second PSQ<sup>™</sup> 96 Plate for a wash in 100 µl of 1X annealing buffer (PYROSEQUENCING<sup>™</sup>). Finally, annealing of the sequencing primers was done by transferring the beads into a third PSQ 96 Plate containing 44 µl of 1X annealing buffer (PYROSEQUENCING<sup>™</sup>) and either 10 pmol of PM1 sequencing primer (5' GTG TTA CCG ATG ATC C 3'; SEQ ID NO: 95) or 10 pmol of PM2 sequencing primer (5' GGG ATG GTC ATG CAA T 3'; SEQ ID NO: 96) for assaying the PM1 and PM2 mutations respectively. This third plate was then incubated at 94°C for 3 minutes and allowed to cool to room temperature for 5 to 10 minutes.

*SNP detection using the PYROSEQUENCING (PSQ<sup>™</sup> 96) system*

**[068]** The third PSQ 96 Plate containing PM1 or PM2 sequencing primers annealed to the non-coding biotinylated strands from each PCR product was loaded onto the PSQ<sup>™</sup> 96 system and the pyrosequencing run was carried out using the PSQ<sup>™</sup> 96 Instrument Control module from the PSQ<sup>™</sup> 96 SNP Software (version 1.2 AQ). The PSQ<sup>™</sup> 96 SNP Entry module was used to enter the orders of dispensing nucleotides for both PM1 and PM2 detection (CTAGCTGTG for "PM1" detection and CTGCAGATC for "PM2" detection) while the PSQ<sup>™</sup> 96 Evaluation module was used for viewing the results of pyrosequencing.

**[069]** The choice of the non-coding sequence as the template and the specific sequencing primers combinations for the "PM1" and "PM2" assay was the result of optimization of the process to produce unambiguous pyrograms that could infer the presence or absence of the mutations and whether they are present in the homozygous or heterozygous state.

*Results of "PM1" and "PM2" tests using Pyrosequencing™*

[070] Using the pyrosequencing technology platform for the "PM1" and "PM2" tests requires that the *AHAS1* and *AHAS3* sequences around the mutations to be amplified separately by specific PCR reactions. In the pyrosequencing technology, the incorporation of each nucleotide with the release of pyrophosphate during the primer extension reaction is coupled to the sulfurylase/luciferase system, which gives light signals proportional to the number of nucleotides incorporated at each elongation step. The results of the pyrosequencing reaction indicate the identity of the nucleotide sequences around the polymorphic site from which the nucleotide at the polymorphic site can be read. With the PM1 test, both *B. napus* 'Topas' and the *B. napus* 'PM2' line have the wildtype *AHAS1* sequence and the sequence extended from the PM1 sequencing primer is CAAGTGGTGG (SEQ ID NO:97); while for the mutant PM1 line, the extended sequence is CAAATGGTGG (SEQ ID NO:98) indicating the G→A PM1 mutation on the coding strand. With the PM2 test, both 'Topas' and the 'PM1' line have wildtype *AHAS3* sequence and the sequence extended from the PM2 sequencing primer is GGGAAGATC (SEQ ID NO:99); while for the mutant PM2 line, the extended sequence is TGGAAGATC (SEQ ID NO:100) indicating the G→T PM2 mutation on the coding strand. Thus both PM1 and PM2 mutations were detected accurately using the PYROSEQUENCING™ technology.

[071] Throughout this application, various publications are referenced. The disclosures of all of these publications and those references cited within those publications in are hereby incorporated by reference in their entireties. It should also be understood that the foregoing relates to preferred embodiments of the present invention and that numerous changes may be made therein without departing from the scope of the invention. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof, which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.

## SEQUENCE LISTING

&lt;110&gt; BASF PLANT SCIENCE GmbH

<120> COMPOSITIONS AND METHODS FOR IDENTIFYING PLANTS HAVING  
INCREASED TOLERANCE TO IMIDAZOLINONE HERBICIDES

&lt;130&gt; 15039-PCT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/421,993

&lt;151&gt; 2002-10-29

&lt;160&gt; 116

&lt;170&gt; PatentIn Ver. 3.2

&lt;210&gt; 1

&lt;211&gt; 2083

&lt;212&gt; DNA

&lt;213&gt; Brassica napus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (25) .. (1989)

&lt;400&gt; 1

tc	at	cat	cat	ctc	tct	ctc	ctc	tca	aacc	atg	gcg	gcg	gca	aca	tcg	tct	tct	ccg	51
										Met	Ala	Ala	Ala	Thr	Ser	Ser	Ser	Pro	
										1					5				
atc	tcc	tta	acc	gct	aaa	cct	tct	tcc	aaa	tcc	cct	cta	ccc	att	tcc	99			
Ile	Ser	Leu	Thr	Ala	Lys	Pro	Ser	Ser	Lys	Ser	Pro	Leu	Pro	Ile	Ser				
10					15					20					25				
aga	ttc	tcc	ctt	ccc	ttc	tcc	tta	acc	cca	cag	aaa	gac	tcc	tcc	cgt	147			
Arg	Phe	Ser	Leu	Pro	Phe	Ser	Leu	Thr	Pro	Gln	Lys	Asp	Ser	Ser	Arg				
				30					35					40					
ctc	cac	cgt	cct	ctc	gcc	atc	tcc	gcc	ggt	ctc	aac	tca	ccc	gtc	aat	195			
Leu	His	Arg	Pro	Leu	Ala	Ile	Ser	Ala	Val	Leu	Asn	Ser	Pro	Val	Asn				
			45					50					55						
gtc	gca	cct	cct	tcc	cct	gaa	aaa	acc	gac	aag	aac	aag	act	ttc	gtc	243			
Val	Ala	Pro	Pro	Ser	Pro	Glu	Lys	Thr	Asp	Lys	Asn	Lys	Thr	Phe	Val				
		60					65					70							
tcc	cgc	tac	gct	ccc	gac	gag	ccc	cgc	aag	ggt	gct	gat	atc	ctc	gtc	291			
Ser	Arg	Tyr	Ala	Pro	Asp	Glu	Pro	Arg	Lys	Gly	Ala	Asp	Ile	Leu	Val				
	75					80					85								

gaa gcc ctc gag cgt caa ggc gtc gaa acc gtc ttt gct tat ccc gga	339
Glu Ala Leu Glu Arg Gln Gly Val Glu Thr Val Phe Ala Tyr Pro Gly	
90 95 100 105	
ggt gct tcc atg gag atc cac caa gcc ttg act cgc tcc tcc acc atc	387
Gly Ala Ser Met Glu Ile His Gln Ala Leu Thr Arg Ser Ser Thr Ile	
110 115 120	
cgt aac gtc ctt ccc cgt cac gaa caa gga gga gtc ttc gcc gcc gag	435
Arg Asn Val Leu Pro Arg His Glu Gln Gly Gly Val Phe Ala Ala Glu	
125 130 135	
ggt tac gct cgt tcc tcc ggc aaa ccg gga atc tgc ata gcc act tcg	483
Gly Tyr Ala Arg Ser Ser Gly Lys Pro Gly Ile Cys Ile Ala Thr Ser	
140 145 150	
ggt ccc gga gct acc aac ctc gtc agc ggg tta gca gac gcg atg ctt	531
Gly Pro Gly Ala Thr Asn Leu Val Ser Gly Leu Ala Asp Ala Met Leu	
155 160 165	
gac agt gtt cct ctt gtc gcc att aca gga cag gtc cct cgc cgg atg	579
Asp Ser Val Pro Leu Val Ala Ile Thr Gly Gln Val Pro Arg Arg Met	
170 175 180 185	
atc ggt act gac gcc ttc caa gag aca cca atc gtt gag gta acg agg	627
Ile Gly Thr Asp Ala Phe Gln Glu Thr Pro Ile Val Glu Val Thr Arg	
190 195 200	
tct att acg aaa cat aac tat ctg gtg atg gat gtt gat gac ata cct	675
Ser Ile Thr Lys His Asn Tyr Leu Val Met Asp Val Asp Asp Ile Pro	
205 210 215	
agg atc gtt caa gaa gca ttc ttt cta gct act tcc ggt aga ccc gga	723
Arg Ile Val Gln Glu Ala Phe Phe Leu Ala Thr Ser Gly Arg Pro Gly	
220 225 230	
ccg gtt ttg gtt gat gtt cct aag gat att cag cag cag ctt gcg att	771
Pro Val Leu Val Asp Val Pro Lys Asp Ile Gln Gln Gln Leu Ala Ile	
235 240 245	
cct aac tgg gat caa cct atg cgc ttg cct ggc tac atg tct agg ttg	819
Pro Asn Trp Asp Gln Pro Met Arg Leu Pro Gly Tyr Met Ser Arg Leu	
250 255 260 265	
cct cag ccw ccg gaa gtt tct cag tta ggt cag atc gtt agg ttg atc	867
Pro Gln Xaa Pro Glu Val Ser Gln Leu Gly Gln Ile Val Arg Leu Ile	
270 275 280	
tcg gag tct aag agg cct gtt ttg tac gtt ggt ggt gga agc ttg aac	915
Ser Glu Ser Lys Arg Pro Val Leu Tyr Val Gly Gly Gly Ser Leu Asn	
285 290 295	



tcg agt gaa gaa ctg ggg aga ttt gtc gag ctt act ggg atc cct gtt	963
Ser Ser Glu Glu Leu Gly Arg Phe Val Glu Leu Thr Gly Ile Pro Val	
300 305 310	
gcg agt acg ttg atg ggg ctt ggc tct tat cct tgt aac gat gag ttg	1011
Ala Ser Thr Leu Met Gly Leu Gly Ser Tyr Pro Cys Asn Asp Glu Leu	
315 320 325	
tcc ctg cag atg ctt ggc atg cac ggg act gtg tat gct aac tac gct	1059
Ser Leu Gln Met Leu Gly Met His Gly Thr Val Tyr Ala Asn Tyr Ala	
330 335 340 345	
gtg gag cat agt gat ttg ttg ctg gcg ttt ggt gtt agg ttt gat gac	1107
Val Glu His Ser Asp Leu Leu Leu Ala Phe Gly Val Arg Phe Asp Asp	
350 355 360	
cgt gtc acg gga aag ctc gag gct ttc gct agc agg gct aaa att gtg	1155
Arg Val Thr Gly Lys Leu Glu Ala Phe Ala Ser Arg Ala Lys Ile Val	
365 370 375	
cac ata gac att gat tct gct gag att ggg aag aat aag aca cct cac	1203
His Ile Asp Ile Asp Ser Ala Glu Ile Gly Lys Asn Lys Thr Pro His	
380 385 390	
gtg tct gtg tgt ggt gat gta aag ctg gct ttg caa ggg atg aac aag	1251
Val Ser Val Cys Gly Asp Val Lys Leu Ala Leu Gln Gly Met Asn Lys	
395 400 405	
gtt ctt gag aac cgg gcg gag gag ctc aag ctt gat ttc ggt gtt tgg	1299
Val Leu Glu Asn Arg Ala Glu Glu Leu Lys Leu Asp Phe Gly Val Trp	
410 415 420 425	
agg agt gag ttg agc gag cag aaa cag aag ttc cct ttg agc ttc aaa	1347
Arg Ser Glu Leu Ser Glu Gln Lys Gln Lys Phe Pro Leu Ser Phe Lys	
430 435 440	
acg ttt gga gaa gcc att cct ccg cag tac gcg att cag atc ctc gac	1395
Thr Phe Gly Glu Ala Ile Pro Pro Gln Tyr Ala Ile Gln Ile Leu Asp	
445 450 455	
gag cta acc gaa ggg aag gca att atc agt act ggt gtt gga cag cgt	1443
Glu Leu Thr Glu Gly Lys Ala Ile Ile Ser Thr Gly Val Gly Gln Arg	
460 465 470	
cag atg tgg gcg gcg cag ttt tac aag tac agg aag ccg aga cag tgg	1491
Gln Met Trp Ala Ala Gln Phe Tyr Lys Tyr Arg Lys Pro Arg Gln Trp	
475 480 485	
ctg tcg tca tca ggc ctc gga gct atg ggt ttt gga ctt cct gct gcg	1539
Leu Ser Ser Ser Gly Leu Gly Ala Met Gly Phe Gly Leu Pro Ala Ala	
490 495 500 505	

att gga gcg tct gtg gcg aac cct gat gcg att gtt gtg gat att gac 1587  
 Ile Gly Ala Ser Val Ala Asn Pro Asp Ala Ile Val Val Asp Ile Asp  
                           510                          515                          520

ggt gat gga agc ttc ata atg aac gtt caa gag ctg gcc aca atc cgt 1635  
 Gly Asp Gly Ser Phe Ile Met Asn Val Gln Glu Leu Ala Thr Ile Arg  
                           525                          530                          535

gta gag aat ctt cct gtg aag ata ctc ttg tta aac aac cag cat ctt 1683  
 Val Glu Asn Leu Pro Val Lys Ile Leu Leu Leu Asn Asn Gln His Leu  
                           540                          545                          550

ggg atg gtc atg caa tgg gaa gat cgg ttc tac aaa gct aac aga gct 1731  
 Gly Met Val Met Gln Trp Glu Asp Arg Phe Tyr Lys Ala Asn Arg Ala  
                           555                          560                          565

cac act tat ctc ggg gac ccg gca agg gag aac gag atc ttc cct aac 1779  
 His Thr Tyr Leu Gly Asp Pro Ala Arg Glu Asn Glu Ile Phe Pro Asn  
 570                          575                          580                          585

atg ctg cag ttt gca gga gct tgc ggg att cca gct gcg aga gtg acg 1827  
 Met Leu Gln Phe Ala Gly Ala Cys Gly Ile Pro Ala Ala Arg Val Thr  
                           590                          595                          600

aag aaa gaa gaa ctc cga gaa gct att cag aca atg ctg gat aca cca 1875  
 Lys Lys Glu Glu Leu Arg Glu Ala Ile Gln Thr Met Leu Asp Thr Pro  
                           605                          610                          615

gga cca tac ctg ttg gat gtg ata tgt ccg cac caa gaa cat gtg tta 1923  
 Gly Pro Tyr Leu Leu Asp Val Ile Cys Pro His Gln Glu His Val Leu  
                           620                          625                          630

ccg atg atc cca aat ggt ggc act ttc aaa gat gta ata aca gaa ggg 1971  
 Pro Met Ile Pro Asn Gly Gly Thr Phe Lys Asp Val Ile Thr Glu Gly  
                           635                          640                          645

gat ggt cgc act aag tac tgagagattm agctgggtgat cgatcatatg 2019  
 Asp Gly Arg Thr Lys Tyr  
 650                          655

gtaaaagact tagtttcagt ttccagtttc ttttgtgtgg taatttgggt ttgtcagttg 2079

ttgt 2083

<210> 2  
 <211> 2116  
 <212> DNA  
 <213> Brassica napus

<220>  
 <221> CDS  
 <222> (43).. (1998)

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1434)..(1434)

&lt;223&gt; a, c, g, t, other or unknown

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (2113)..(2113)

&lt;223&gt; a, c, g, t, other or unknown

&lt;400&gt; 2

```

ttcatcatmt ctctctcatt tctctctctc tctcatctaa cc atg gcg gcg gca      54
                                     Met Ala Ala Ala
                                       1

aca tcg tct tct ccg atc tcc tta acc gct aaa cct tct tcc aaa tcc      102
Thr Ser Ser Ser Pro Ile Ser Leu Thr Ala Lys Pro Ser Ser Lys Ser
   5                               10                               15                               20

cct cta ccc att tcc aga ttc tcc ctt ccc ttc tcc tta acc cca cag      150
Pro Leu Pro Ile Ser Arg Phe Ser Leu Pro Phe Ser Leu Thr Pro Gln
                               25                               30                               35

aaa ccc tcc tcc cgt ctc cac cgt cca ctc gcc atc tcc gcc gtt ctc      198
Lys Pro Ser Ser Arg Leu His Arg Pro Leu Ala Ile Ser Ala Val Leu
                               40                               45                               50

aac tca ccc gtc aat gtc gca cct gaa aaa acc gac aag atc aag act      246
Asn Ser Pro Val Asn Val Ala Pro Glu Lys Thr Asp Lys Ile Lys Thr
                               55                               60                               65

ttc atc tcc cgc tac gct ccc gac gag ccc cgc aag ggt gct gat atc      294
Phe Ile Ser Arg Tyr Ala Pro Asp Glu Pro Arg Lys Gly Ala Asp Ile
   70                               75                               80

ctc gtg gaa gcc ctc gag cgt caa ggc gtc gaa acc gtc ttc gct tat      342
Leu Val Glu Ala Leu Glu Arg Gln Gly Val Glu Thr Val Phe Ala Tyr
   85                               90                               95                               100

ccc gga ggt gcc tcc atg gag atc cac caa gcc ttg act cgc tcc tcc      390
Pro Gly Gly Ala Ser Met Glu Ile His Gln Ala Leu Thr Arg Ser Ser
                               105                               110                               115

acc atc cgt aac gtc ctc ccc cgt cac gaa caa gga gga gtc ttc gcc      438
Thr Ile Arg Asn Val Leu Pro Arg His Glu Gln Gly Gly Val Phe Ala
                               120                               125                               130

gcc gag ggt tac gct cgt tcc tcc ggc aaa ccg gga atc tgc ata gcc      486
Ala Glu Gly Tyr Ala Arg Ser Ser Gly Lys Pro Gly Ile Cys Ile Ala
                               135                               140                               145

act tcg ggt ccc gga gct acc aac ctc gtc agc ggg tta gcc gac gcg      534
Thr Ser Gly Pro Gly Ala Thr Asn Leu Val Ser Gly Leu Ala Asp Ala
   150                               155                               160

```

atg ctt gac agt gtt cct ctc gtc gcc atc aca gga cag gtc cct cgc	582
Met Leu Asp Ser Val Pro Leu Val Ala Ile Thr Gly Gln Val Pro Arg	
165	170 175 180
cgg atg atc ggt act gac gcg ttc caa gag acg cca atc gtt gag gta	630
Arg Met Ile Gly Thr Asp Ala Phe Gln Glu Thr Pro Ile Val Glu Val	
185	190 195
acg agg tct att acg aaa cat aac tat ctg gtg atg gat gtt gat gac	678
Thr Arg Ser Ile Thr Lys His Asn Tyr Leu Val Met Asp Val Asp Asp	
200	205 210
ata cct agg atc gtt caa gaa gca ttc ttt cta gct act tcc ggt aga	726
Ile Pro Arg Ile Val Gln Glu Ala Phe Phe Leu Ala Thr Ser Gly Arg	
215	220 225
ccc gga ccg gtt ttg gtt gat gtt cct aag gat att cag cag cag ctt	774
Pro Gly Pro Val Leu Val Asp Val Pro Lys Asp Ile Gln Gln Gln Leu	
230	235 240
gcg att cct aac tgg gat caa cct atg cgc ttg cct ggc tac atg tct	822
Ala Ile Pro Asn Trp Asp Gln Pro Met Arg Leu Pro Gly Tyr Met Ser	
245	250 255 260
agg ctg cct cag cca ccg gaa gtt tct cag tta ggc cag atc gtt agg	870
Arg Leu Pro Gln Pro Pro Glu Val Ser Gln Leu Gly Gln Ile Val Arg	
265	270 275
ttg atc tcg gag tct aag agg cct gtt ttg tac gtt ggt ggt gga agc	918
Leu Ile Ser Glu Ser Lys Arg Pro Val Leu Tyr Val Gly Gly Gly Ser	
280	285 290
ttg aac tcg agt gaa gaa ctg ggg aga ttt gtc gag ctt act ggg atc	966
Leu Asn Ser Ser Glu Glu Leu Gly Arg Phe Val Glu Leu Thr Gly Ile	
295	300 305
cct gtt gcg agt acg ctg atg ggg ctt ggc tct tat cct tgt aac gat	1014
Pro Val Ala Ser Thr Leu Met Gly Leu Gly Ser Tyr Pro Cys Asn Asp	
310	315 320
gag ttg tcc ctg cag atg ctt ggc atg cac ggg act gtg tat gct aac	1062
Glu Leu Ser Leu Gln Met Leu Gly Met His Gly Thr Val Tyr Ala Asn	
325	330 335 340
tac gct gtg gag cat agt gat ttg ttg ctg gcg ttt ggt gtt agg ttt	1110
Tyr Ala Val Glu His Ser Asp Leu Leu Leu Ala Phe Gly Val Arg Phe	
345	350 355
gat gac cgt gtc acg gga aag ctc gag gcg ttt gcg agc agg gct aag	1158
Asp Asp Arg Val Thr Gly Lys Leu Glu Ala Phe Ala Ser Arg Ala Lys	
360	365 370

att gtg cac ata gac att gat tct gct gag att ggg aag aat aag aca	1206
Ile Val His Ile Asp Ile Asp Ser Ala Glu Ile Gly Lys Asn Lys Thr	
375 380 385	
cct cac gtg tct gtg tgt ggt gat gta aag ctg gct ttg caa ggg atg	1254
Pro His Val Ser Val Cys Gly Asp Val Lys Leu Ala Leu Gln Gly Met	
390 395 400	
aac aag gtt ctt gag aac cgg gcg gag gag ctc aag ctt gat ttc ggt	1302
Asn Lys Val Leu Glu Asn Arg Ala Glu Glu Leu Lys Leu Asp Phe Gly	
405 410 415 420	
gtt tgg agg agt gag ttg agc gag cag aaa cag aag ttc ccg ttg agc	1350
Val Trp Arg Ser Glu Leu Ser Glu Gln Lys Gln Lys Phe Pro Leu Ser	
425 430 435	
ttc aaa acg ttt gga gaa gcc att cct ccg cag tac gcg att cag gtc	1398
Phe Lys Thr Phe Gly Glu Ala Ile Pro Pro Gln Tyr Ala Ile Gln Val	
440 445 450	
cta gac gag cta acc caa ggg aag gca att atc agn act ggt gtt gga	1446
Leu Asp Glu Leu Thr Gln Gly Lys Ala Ile Ile Xaa Thr Gly Val Gly	
455 460 465	
cag cat cag atg tgg gcg gcg cag ttt tac aag tac agg aag ccg agg	1494
Gln His Gln Met Trp Ala Ala Gln Phe Tyr Lys Tyr Arg Lys Pro Arg	
470 475 480	
cag tgg ctg tcg tcc tca gga ctc gga gct atg ggt ttc gga ctt cct	1542
Gln Trp Leu Ser Ser Ser Gly Leu Gly Ala Met Gly Phe Gly Leu Pro	
485 490 495 500	
gct gcg att gga gcg tct gtg gcg aac cct gat gcg att gtt gtg gac	1590
Ala Ala Ile Gly Ala Ser Val Ala Asn Pro Asp Ala Ile Val Val Asp	
505 510 515	
att gac ggt gat gga agc ttc ata atg aac gtt caa gag ctg gcc aca	1638
Ile Asp Gly Asp Gly Ser Phe Ile Met Asn Val Gln Glu Leu Ala Thr	
520 525 530	
atc cgt gta gag aat ctt cct gtg aag ata ctc ttg tta aac aac cag	1686
Ile Arg Val Glu Asn Leu Pro Val Lys Ile Leu Leu Leu Asn Asn Gln	
535 540 545	
cat ctt ggg atg gtc atg caa ttg gaa gat cgg ttc tac aaa gct aac	1734
His Leu Gly Met Val Met Gln Leu Glu Asp Arg Phe Tyr Lys Ala Asn	
550 555 560	
aga gct cac act tat ctc ggg gac ccg gca agg gag aac gag atc ttc	1782
Arg Ala His Thr Tyr Leu Gly Asp Pro Ala Arg Glu Asn Glu Ile Phe	
565 570 575 580	

cct aac atg ctg cag ttt gca gga gct tgc ggg att cca gct gcg aga 1830  
 Pro Asn Met Leu Gln Phe Ala Gly Ala Cys Gly Ile Pro Ala Ala Arg  
 585 590 595

gtg acg aag aaa gaa gaa ctc cga gaa gct att cag aca atg ctg gat 1878  
 Val Thr Lys Lys Glu Glu Leu Arg Glu Ala Ile Gln Thr Met Leu Asp  
 600 605 610

aca cct gga ccg tac ctg ttg gat gcc atc tgt ccg cac caa gaa cat 1926  
 Thr Pro Gly Pro Tyr Leu Leu Asp Ala Ile Cys Pro His Gln Glu His  
 615 620 625

gtg tta ccg atg atc cca agt ggt ggc act ttc aaa gat gta ata acc 1974  
 Val Leu Pro Met Ile Pro Ser Gly Gly Thr Phe Lys Asp Val Ile Thr  
 630 635 640

gaa ggg gat ggt cgc act aag tac tgagagatga agctgggtgat ccatcgtatg 2028  
 Glu Gly Asp Gly Arg Thr Lys Tyr  
 645 650

gtaaaagact tagtttcagt tttcagtttc ttttgtgtgg taatttgggt ttgtcagttg 2088

ttgttytgct tttggtttgt tcccnkac 2116

<210> 3  
 <211> 2083  
 <212> DNA  
 <213> Brassica napus

<220>  
 <221> CDS  
 <222> (25)..(1989)

<400> 3

tcatcatctc tctctcctct aacc atg gcg gcg gca aca tcg tct tct ccg 51  
 Met Ala Ala Ala Thr Ser Ser Ser Pro  
 1 5

atc tcc tta acc gct aaa cct tct tcc aaa tcc cct cta ccc att tcc 99  
 Ile Ser Leu Thr Ala Lys Pro Ser Ser Lys Ser Pro Leu Pro Ile Ser  
 10 15 20 25

aga ttc tcc ctt ccc ttc tcc tta acc cca cag aaa gac tcc tcc cgt 147  
 Arg Phe Ser Leu Pro Phe Ser Leu Thr Pro Gln Lys Asp Ser Ser Arg  
 30 35 40

ctc cac cgt cct ctc gcc atc tcc gcc gtt ctc aac tca ccc gtc aat 195  
 Leu His Arg Pro Leu Ala Ile Ser Ala Val Leu Asn Ser Pro Val Asn  
 45 50 55

gtc gca cct cct tcc cct gaa aaa acc gac aag aac aag act ttc gtc 243  
 Val Ala Pro Pro Ser Pro Glu Lys Thr Asp Lys Asn Lys Thr Phe Val  
 60 65 70

tcc cgc tac gct ccc gac gag ccc cgc aag ggt gct gat atc ctc gtc	291
Ser Arg Tyr Ala Pro Asp Glu Pro Arg Lys Gly Ala Asp Ile Leu Val	
75 80 85	
gaa gcc ctc gag cgt caa ggc gtc gaa acc gtc ttt gct tat ccc gga	339
Glu Ala Leu Glu Arg Gln Gly Val Glu Thr Val Phe Ala Tyr Pro Gly	
90 95 100 105	
ggg gct tcc atg gag atc cac caa gcc ttg act cgc tcc tcc acc atc	387
Gly Ala Ser Met Glu Ile His Gln Ala Leu Thr Arg Ser Ser Thr Ile	
110 115 120	
cgt aac gtc ctt ccc cgt cac gaa caa gga gga gtc ttc gcc gcc gag	435
Arg Asn Val Leu Pro Arg His Glu Gln Gly Gly Val Phe Ala Ala Glu	
125 130 135	
ggg tac gct cgt tcc tcc ggc aaa ccg gga atc tgc ata gcc act tcg	483
Gly Tyr Ala Arg Ser Ser Gly Lys Pro Gly Ile Cys Ile Ala Thr Ser	
140 145 150	
ggg ccc gga gct acc aac ctc gtc agc ggg tta gca gac gcg atg ctt	531
Gly Pro Gly Ala Thr Asn Leu Val Ser Gly Leu Ala Asp Ala Met Leu	
155 160 165	
gac agt gtt cct ctt gtc gcc att aca gga cag gtc cct cgc cgg atg	579
Asp Ser Val Pro Leu Val Ala Ile Thr Gly Gln Val Pro Arg Arg Met	
170 175 180 185	
atc ggt act gac gcc ttc caa gag aca cca atc gtt gag gta acg agg	627
Ile Gly Thr Asp Ala Phe Gln Glu Thr Pro Ile Val Glu Val Thr Arg	
190 195 200	
tct att acg aaa cat aac tat ttg gtg atg gat gtt gat gac ata cct	675
Ser Ile Thr Lys His Asn Tyr Leu Val Met Asp Val Asp Asp Ile Pro	
205 210 215	
agg atc gtt caa gaa gct ttc ttt cta gct act tcc ggt aga ccc gga	723
Arg Ile Val Gln Glu Ala Phe Phe Leu Ala Thr Ser Gly Arg Pro Gly	
220 225 230	
ccg gtt ttg gtt gat gtt cct aag gat att cag cag cag ctt gcg att	771
Pro Val Leu Val Asp Val Pro Lys Asp Ile Gln Gln Gln Leu Ala Ile	
235 240 245	
cct aac tgg gat caa cct atg cgc tta cct ggc tac atg tct agg ttg	819
Pro Asn Trp Asp Gln Pro Met Arg Leu Pro Gly Tyr Met Ser Arg Leu	
250 255 260 265	
cct cag cct ccg gaa gtt tct cag tta ggt cag atc gtt agg ttg atc	867
Pro Gln Pro Pro Glu Val Ser Gln Leu Gly Gln Ile Val Arg Leu Ile	
270 275 280	

tcg gag tct aag agg cct gtt ttg tac gtt ggt ggt gga agc ttg aac 915  
 Ser Glu Ser Lys Arg Pro Val Leu Tyr Val Gly Gly Gly Ser Leu Asn  
 285 290 295

tcg agt gaa gaa ctg ggg aga ttt gtc gag ctt act ggg atc ccc gtt 963  
 Ser Ser Glu Glu Leu Gly Arg Phe Val Glu Leu Thr Gly Ile Pro Val  
 300 305 310

gcg agt act ttg atg ggg ctt ggc tct tat cct tgt aac gat gag ttg 1011  
 Ala Ser Thr Leu Met Gly Leu Gly Ser Tyr Pro Cys Asn Asp Glu Leu  
 315 320 325

tcc ctg cag atg ctt ggc atg cac ggg act gtg tat gct aac tac gct 1059  
 Ser Leu Gln Met Leu Gly Met His Gly Thr Val Tyr Ala Asn Tyr Ala  
 330 335 340 345

gtg gag cat agt gat ttg ttg ctg gcg ttt ggt gtt agg ttt gat gac 1107  
 Val Glu His Ser Asp Leu Leu Leu Ala Phe Gly Val Arg Phe Asp Asp  
 350 355 360

cgt gtc acg gga aag ctc gag gct ttc gct agc agg gct aaa att gtg 1155  
 Arg Val Thr Gly Lys Leu Glu Ala Phe Ala Ser Arg Ala Lys Ile Val  
 365 370 375

cac ata gac att gat tct gct gag att ggg aag aat aag aca cct cac 1203  
 His Ile Asp Ile Asp Ser Ala Glu Ile Gly Lys Asn Lys Thr Pro His  
 380 385 390

gtg tct gtg tgt ggt gat gta aag ctg gct ttg caa ggg atg aac aag 1251  
 Val Ser Val Cys Gly Asp Val Lys Leu Ala Leu Gln Gly Met Asn Lys  
 395 400 405

gtt ctt gag aac cgg gcg gag gag ctc aag ctt gat ttc ggt gtt tgg 1299  
 Val Leu Glu Asn Arg Ala Glu Glu Leu Lys Leu Asp Phe Gly Val Trp  
 410 415 420 425

agg agt gag ttg agc gag cag aaa cag aag ttc cct ttg agc ttc aaa 1347  
 Arg Ser Glu Leu Ser Glu Gln Lys Gln Lys Phe Pro Leu Ser Phe Lys  
 430 435 440

acg ttt gga gaa gcc att cct ccg cag tac gcg att cag atc ctc gac 1395  
 Thr Phe Gly Glu Ala Ile Pro Pro Gln Tyr Ala Ile Gln Ile Leu Asp  
 445 450 455

gag cta acc gaa ggg aag gca att atc agt act ggt gtt gga cag cat 1443  
 Glu Leu Thr Glu Gly Lys Ala Ile Ile Ser Thr Gly Val Gly Gln His  
 460 465 470

cag atg tgg gcg gcg cag ttt tac aag tac agg aag ccg aga cag tgg 1491  
 Gln Met Trp Ala Ala Gln Phe Tyr Lys Tyr Arg Lys Pro Arg Gln Trp  
 475 480 485



ctg tcg tca tca ggc ctc gga gct atg ggt ttt gga ctt cct gct gcg 1539  
 Leu Ser Ser Ser Gly Leu Gly Ala Met Gly Phe Gly Leu Pro Ala Ala  
 490 495 500 505

att gga gcg tct gtg gcg aac cct gat gcg att gtt gtg gat att gac 1587  
 Ile Gly Ala Ser Val Ala Asn Pro Asp Ala Ile Val Val Asp Ile Asp  
 510 515 520

ggt gat gga agc ttc ata atg aac gtt caa gag ctg gcc aca atc cgt 1635  
 Gly Asp Gly Ser Phe Ile Met Asn Val Gln Glu Leu Ala Thr Ile Arg  
 525 530 535

gta gag aat ctt cct gtg aag ata ctc ttg tta aac aac cag cat ctt 1683  
 Val Glu Asn Leu Pro Val Lys Ile Leu Leu Leu Asn Asn Gln His Leu  
 540 545 550

ggg atg gtc atg caa tgg gaa gat cgg ttc tac aaa gct aac aga gct 1731  
 Gly Met Val Met Gln Trp Glu Asp Arg Phe Tyr Lys Ala Asn Arg Ala  
 555 560 565

cac act tat ctc ggg gac ccg gca agg gag aac gag atc ttc cct aac 1779  
 His Thr Tyr Leu Gly Asp Pro Ala Arg Glu Asn Glu Ile Phe Pro Asn  
 570 575 580 585

atg ctg cag ttt gca gga gct tgc ggg att cca gct gcg aga gtg acg 1827  
 Met Leu Gln Phe Ala Gly Ala Cys Gly Ile Pro Ala Ala Arg Val Thr  
 590 595 600

aag aaa gaa gaa ctc cga gaa gct att cag aca atg ctg gat aca cca 1875  
 Lys Lys Glu Glu Leu Arg Glu Ala Ile Gln Thr Met Leu Asp Thr Pro  
 605 610 615

gga cca tac ctg ttg gat gtg ata tgt ccg cac caa gaa cat gtg tta 1923  
 Gly Pro Tyr Leu Leu Asp Val Ile Cys Pro His Gln Glu His Val Leu  
 620 625 630

ccg atg atc cca agt ggt ggc act ttc aaa gat gta ata aca gaa ggg 1971  
 Pro Met Ile Pro Ser Gly Gly Thr Phe Lys Asp Val Ile Thr Glu Gly  
 635 640 645

gat ggt cgc act aag tac tgagagatga agctgggtgat cgatcatatg 2019  
 Asp Gly Arg Thr Lys Tyr  
 650 655

gtaaaagact tagtttcagt ttccagtttc ttttgtgtgg taatttgggt ttgtcagttg 2079

ttgt 2083

&lt;210&gt; 4

&lt;211&gt; 2116

&lt;212&gt; DNA

&lt;213&gt; Brassica napus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (43)..(1998)

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (21)..(21)

&lt;223&gt; a, c, g, t, other or unknown

&lt;400&gt; 4

```

ttmmacatct ctctctcatt ncactctctc cctcatctaa cc atg gcg gcg gca      54
                                     Met Ala Ala Ala
                                     1

aca tcg cct tct ccg atc tcc tta acc gct aaa cct tct tcc aaa tcc      102
Thr Ser Pro Ser Pro Ile Ser Leu Thr Ala Lys Pro Ser Ser Lys Ser
   5                10                15                20

cct cta ccc att tcc aga ttc tcc ctt ccc ttc tcc tta acc cca cag      150
Pro Leu Pro Ile Ser Arg Phe Ser Leu Pro Phe Ser Leu Thr Pro Gln
                25                30                35

aaa ccc tcc tcc cgt ctc cac cgt cca ctc gcc atc tcc gcc gtt ctc      198
Lys Pro Ser Ser Arg Leu His Arg Pro Leu Ala Ile Ser Ala Val Leu
                40                45                50

aac tca ccc gtc aat gtc gca cct gaa aaa acc gac aag atc aag act      246
Asn Ser Pro Val Asn Val Ala Pro Glu Lys Thr Asp Lys Ile Lys Thr
                55                60                65

ttc atc tcc cgc tac gct ccc gac gag ccc cgc aag ggt gct gat atc      294
Phe Ile Ser Arg Tyr Ala Pro Asp Glu Pro Arg Lys Gly Ala Asp Ile
   70                75                80

ctc gtg gaa gcc ctc gag cgt caa ggc gtc gaa acc gtc ttc gct tat      342
Leu Val Glu Ala Leu Glu Arg Gln Gly Val Glu Thr Val Phe Ala Tyr
   85                90                95                100

ccc gga ggt gcc tcc atg gag atc cac caa gcc ttg act cgc tcc tcc      390
Pro Gly Gly Ala Ser Met Glu Ile His Gln Ala Leu Thr Arg Ser Ser
                105                110                115

acc atc cgt aac gtc ctc ccc cgt cac gaa caa gga gga gtc ttc gcc      438
Thr Ile Arg Asn Val Leu Pro Arg His Glu Gln Gly Gly Val Phe Ala
                120                125                130

gcc gag ggt tac gct cgt tcc tcc ggc aaa ccg gga atc tgc ata gcc      486
Ala Glu Gly Tyr Ala Arg Ser Ser Gly Lys Pro Gly Ile Cys Ile Ala
                135                140                145

act tcg ggt ccc gga gct acc aac ctc gtc agc ggg tta gcc gac gcg      534
Thr Ser Gly Pro Gly Ala Thr Asn Leu Val Ser Gly Leu Ala Asp Ala
   150                155                160

```

atg ctt gac agt gtt cct ctc gtc gcc atc aca gga cag gtc cct cgc	582
Met Leu Asp Ser Val Pro Leu Val Ala Ile Thr Gly Gln Val Pro Arg	
165	170 175 180
cgg atg atc ggt act gac gcg ttc caa gag acg cca atc gtt gag gta	630
Arg Met Ile Gly Thr Asp Ala Phe Gln Glu Thr Pro Ile Val Glu Val	
185	190 195
acg agg tct att acg aaa cat aac tat ctg gtg atg gat gtt gat gac	678
Thr Arg Ser Ile Thr Lys His Asn Tyr Leu Val Met Asp Val Asp Asp	
200	205 210
ata cct agg atc gtt caa gaa gca ttc ttt cta gct act tcc ggt aga	726
Ile Pro Arg Ile Val Gln Glu Ala Phe Phe Leu Ala Thr Ser Gly Arg	
215	220 225
ccc gga ccg gtt ttg gtt gat gtt cct aag gat att cag cag cag ctt	774
Pro Gly Pro Val Leu Val Asp Val Pro Lys Asp Ile Gln Gln Gln Leu	
230	235 240
gcg att cct aac tgg gat caa cct atg cgc ttg cct ggc tac atg tct	822
Ala Ile Pro Asn Trp Asp Gln Pro Met Arg Leu Pro Gly Tyr Met Ser	
245	250 255 260
agg ctg cct cag cca ccg gaa gtt tct cag tta ggc cag atc gtt agg	870
Arg Leu Pro Gln Pro Pro Glu Val Ser Gln Leu Gly Gln Ile Val Arg	
265	270 275
ttg atc tcg gag tct aag agg cct gtt ttg tac gtt ggt ggt gga agc	918
Leu Ile Ser Glu Ser Lys Arg Pro Val Leu Tyr Val Gly Gly Gly Ser	
280	285 290
ttg aac tcg agt gag gaa ctg ggg aga ttt gtc gag ctt act ggg atc	966
Leu Asn Ser Ser Glu Glu Leu Gly Arg Phe Val Glu Leu Thr Gly Ile	
295	300 305
cct gtt gcg agt acg ttg atg ggg ctt ggc tct tat cct tgt aac gat	1014
Pro Val Ala Ser Thr Leu Met Gly Leu Gly Ser Tyr Pro Cys Asn Asp	
310	315 320
gag ttg tcc ctg cag atg ctt ggc atg cac ggg act gtg tat gct aac	1062
Glu Leu Ser Leu Gln Met Leu Gly Met His Gly Thr Val Tyr Ala Asn	
325	330 335 340
tac gct gtg gag cat agt gat ttg ttg ctg gcg ttt ggt gtt agg ttt	1110
Tyr Ala Val Glu His Ser Asp Leu Leu Leu Ala Phe Gly Val Arg Phe	
345	350 355
gat gac cgt gtc acg gga aag ctc gag gcg ttt gcg agc agg gct aag	1158
Asp Asp Arg Val Thr Gly Lys Leu Glu Ala Phe Ala Ser Arg Ala Lys	
360	365 370

att gtg cac ata gac att gat tct gct gag att ggg aag aat aag aca Ile Val His Ile Asp Ile Asp Ser Ala Glu Ile Gly Lys Asn Lys Thr 375 380 385	1206
cct cac gtg tct gtg tgt ggt gat gta aag ctg gct ttg caa ggg atg Pro His Val Ser Val Cys Gly Asp Val Lys Leu Ala Leu Gln Gly Met 390 395 400	1254
aac aag gtt ctt gag aac cgg gcg gag gag ctc aag ctt gat ttc ggt Asn Lys Val Leu Glu Asn Arg Ala Glu Glu Leu Lys Leu Asp Phe Gly 405 410 415 420	1302
gtt tgg agg agt gag ttg agc gag cag aaa cag aag ttc ccg ttg agc Val Trp Arg Ser Glu Leu Ser Glu Gln Lys Gln Lys Phe Pro Leu Ser 425 430 435	1350
ttc aaa acg ttt gga gaa gcc att cct ccg cag tac gcg att cag gtc Phe Lys Thr Phe Gly Glu Ala Ile Pro Pro Gln Tyr Ala Ile Gln Val 440 445 450	1398
cta gac gag cta acc caa ggg aag gca att atc agt act ggt gtt gga Leu Asp Glu Leu Thr Gln Gly Lys Ala Ile Ile Ser Thr Gly Val Gly 455 460 465	1446
cag cat cag atg tgg gcg gcg cag ttt tac aag tac agg aag ccg agg Gln His Gln Met Trp Ala Ala Gln Phe Tyr Lys Tyr Arg Lys Pro Arg 470 475 480	1494
cag tgg ctg tgg tcc tca gga ctc gga gct atg ggt ttc gga ctt cct Gln Trp Leu Ser Ser Ser Gly Leu Gly Ala Met Gly Phe Gly Leu Pro 485 490 495 500	1542
gct gcg att gga gcg tct gtg gcg aac cct gat gcg att gtt gtg gac Ala Ala Ile Gly Ala Ser Val Ala Asn Pro Asp Ala Ile Val Val Asp 505 510 515	1590
att gac ggt gat gga agc ttc ata atg aac gtt caa gag ctg gcc aca Ile Asp Gly Asp Gly Ser Phe Ile Met Asn Val Gln Glu Leu Ala Thr 520 525 530	1638
atc cgt gta gag aat ctt cct gtg aag ata ctc ttg tta aac aac cag Ile Arg Val Glu Asn Leu Pro Val Lys Ile Leu Leu Leu Asn Asn Gln 535 540 545	1686
cat ctt ggg atg gtc atg caa tgg gaa gat cgg ttc tac aaa gct aac His Leu Gly Met Val Met Gln Trp Glu Asp Arg Phe Tyr Lys Ala Asn 550 555 560	1734
aga gct cac act tat ctc ggg gac ccg gca agg gag aac gag atc ttc Arg Ala His Thr Tyr Leu Gly Asp Pro Ala Arg Glu Asn Glu Ile Phe 565 570 575 580	1782

cct aac atg ctg cag ttt gca gga gct tgc ggg att cca gct gcg aga 1830  
 Pro Asn Met Leu Gln Phe Ala Gly Ala Cys Gly Ile Pro Ala Ala Arg  
                     585                                    590                                    595

gtg acg aag aaa gaa gaa ctc cga gaa gct att cag aca atg ctg gat 1878  
 Val Thr Lys Lys Glu Glu Leu Arg Glu Ala Ile Gln Thr Met Leu Asp  
                     600                                    605                                    610

aca cct gga ccg tac ctg ttg gat gtc atc tgt ccg cac caa gaa cat 1926  
 Thr Pro Gly Pro Tyr Leu Leu Asp Val Ile Cys Pro His Gln Glu His  
                     615                                    620                                    625

gtg tta ccg atg atc cca agt ggt ggc act ttc gaa gat gta ata acc 1974  
 Val Leu Pro Met Ile Pro Ser Gly Gly Thr Phe Glu Asp Val Ile Thr  
                     630                                    635                                    640

gaa ggg gat ggt cgc act aag tac tgagagatga agctggatgat ccatcatatg 2028  
 Glu Gly Asp Gly Arg Thr Lys Tyr  
 645                                    650

gtaaaagact tagtttcagt ttacagtttc ttttgtgtgg taatttgggt ttgtcagttg 2088

ttgttctgct tttggtttgt tcccwkac 2116

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 oligonucleotide

<400> 5

ttatctcggg gacccggcaa

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
 oligonucleotide

<400> 6

gacccggcaa gggagaacga

20

<210> 7  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 7  
gggagaacga gatcttcct 20

<210> 8  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 8  
gatcttcct aacatgctgc 20

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 9  
aacatgctgc agtttgcagg 20

<210> 10  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 10  
agtttgcagg agcttgcggg 20

<210> 11  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 11  
agcttgcggg attccagctg

20

<210> 12  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 12  
attccagctg cgagagtgac

20

<210> 13  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 13  
cgagagtgac gaagaaagaa

20

<210> 14  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 14  
gaagaaagaa gaactccgag

20

<210> 15  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 15  
gaactccgag aagctattca

20

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 16  
aagctattca gacaatgctg

20

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 17  
gacaatgctg gatacaccag

20

<210> 18  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 18  
gatacaccag gaccatacct

20



<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 19

gaccatacct gttggatgtg

20

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 20

gttggatgtg atatgtccgc

20

<210> 21  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 21

atatgtccgc accaagaaca

20

<210> 22  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 22

accaagaaca tgtggtaccg

20

<210> 23  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 23  
tgtgttaccg atgatcccaa

20

<210> 24  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 24  
catctttgaa agtgccacca

20

<210> 25  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 25  
tctggtatta catctttgaa

20

<210> 26  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 26  
accatcccct tctggtatta

20

<210> 27  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 27  
acttagtgcg accatcccct

20

<210> 28  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 28  
atctctcagt acttagtgcg

20

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 29  
caccagcttc atctctcagt

20

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 30  
tatgatcgat caccagcttc

20

<210> 31  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 31  
tcttttacca tatgatcgat 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 32  
tgaaactaag tcttttacca 20

<210> 33  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 33  
aactggaaac tgaaactaag 20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 34  
acacaaaaga aactggaaac 20

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 35  
ccaaattacc acacaaaaga 20

<210> 36  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 36  
actgacaaac ccaaattacc 20

<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 37  
tagtacaaca actgacaaac 20

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 38  
caaccaaag tagtacaaca 20

<210> 39  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 39  
cgtctgggaa caaccaaag

20

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 40  
acagcgagta cgtctgggaa

20

<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 41  
caaaacaaca acagcgagta

20

<210> 42  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 42  
aaaaggaaa caaaacaaca

20

<210> 43  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 43  
atgatcccaa gtggtggcac t 21

<210> 44  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 44  
agtgccacca cttgggatca t 21

<210> 45  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 45  
atgatcccaa atggtggcac t 21

<210> 46  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 46  
agtgccacca tttgggatca t 21

<210> 47  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 47  
ctcaggactc ggagctatgg

20

<210> 48  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 48  
ggagctatgg gtttcggact

20

<210> 49  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 49  
gtttcggact tcctgctgcg

20

<210> 50  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 50  
tcctgctgcg attggagcgt

20



<210> 51  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 51  
attggagcgt ctgtggcgaa 20

<210> 52  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 52  
ctgtggcgaa ccctgatgcg 20

<210> 53  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 53  
ccctgatgcg attgttgtgg 20

<210> 54  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 54  
attgttgtgg acattgacgg 20

<210> 55  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 55  
acattgacgg tgatggaagc

20

<210> 56  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 56  
tgatggaagc ttcataatga

20

<210> 57  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 57  
ttcataatga acgttcaaga

20

<210> 58  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 58  
acgttcaaga gctggccaca

20

<210> 59  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 59  
gctggccaca atccgtgtag

20

<210> 60  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 60  
atccgtgtag agaattctcc

20

<210> 61  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 61  
agaattctcc tgtgaagata

20

<210> 62  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 62  
tgtgaagata ctcttgtaa

20

<210> 63  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 63  
ctcttgtaa acaaccagca

20

<210> 64  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 64  
acaaccagca tcttgggatg

20

<210> 65  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 65  
tcttgggatg gtcattgcaat

20

<210> 66  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 66  
ctttgtagaa ccgatcttcc

20

<210> 67  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 67  
gctctgtag cttttagaa

20

<210> 68  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 68  
ataagtgtga gctctgtag

20

<210> 69  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 69  
ggtccccgag ataagtgtga

20

<210> 70  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 70  
tccdtgccc ggtccccgag

20

<210> 71  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 71  
gatctcgttc tcccttgccg

20

<210> 72  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 72  
tgtagggaa gatctcgttc

20

<210> 73  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 73  
aactgcagca tgtagggaa

20

<210> 74  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 74  
agctcctgca aactgcagca

20

<210> 75  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 75  
gaatcccgca agtcctgca 20

<210> 76  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 76  
ctcgcagctg gaatcccgca 20

<210> 77  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 77  
cttcgctcact ctcgcagctg 20

<210> 78  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 78  
gttcttcttt cttcgctcact 20

<210> 79  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 79  
gcttctcgga gttcttcttt

20

<210> 80  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 80  
tgtctgaata gcttctcgga

20

<210> 81  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 81  
tatccagcat tgtctgaata

20

<210> 82  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 82  
ggtccagggtg tatccagcat

20



<210> 83  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 83  
caacaggtac ggtccaggtg

20

<210> 84  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 84  
agatgacatc caacaggtac

20

<210> 85  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 85  
gtcatgcaat ggggaagatcg g

21

<210> 86  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 86  
ccgatcttcc cattgcatga c

<210> 87  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 87  
gtcatgcaat tggaagatcg g

21

<210> 88  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 88  
ccgatcttcc aattgcatga c

21

<210> 89  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
primer

<400> 89  
tacatctttg aaagtgcca

19

<210> 90  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
primer

<400> 90  
ggcgtttggt gttaggtttg a

21

<210> 91  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 91  
cgtctgggaa caaccaaag t 21

<210> 92  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 92  
ggaaagctcg aggctttcgc t 21

<210> 93  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 93  
atcaccagct tcattctca gt 22

<210> 94  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 94  
ggaaagctcg aggcgcttgc g 21

<210> 95  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 95  
gtggtaccga tgatcc 16

<210> 96  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 96  
gggatggtca tgcaat 16

<210> 97  
<211> 10  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 97  
caagtgggtgg 10

<210> 98  
<211> 10  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 98  
caaagtgggtgg 10

<210> 99  
 <211> 9  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic primer

<400> 99  
 ggggaagatc

9

<210> 100  
 <211> 9  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic primer

<400> 100  
 tggaagatc

9

<210> 101  
 <211> 655  
 <212> PRT  
 <213> Brassica napus

<220>  
 <221> MOD\_RES  
 <222> (268)..(268)  
 <223> Variable amino acid

<400> 101  
 Met Ala Ala Ala Thr Ser Ser Ser Pro Ile Ser Leu Thr Ala Lys Pro  
   1                  5                  10                  15  
 Ser Ser Lys Ser Pro Leu Pro Ile Ser Arg Phe Ser Leu Pro Phe Ser  
                   20                  25                  30  
 Leu Thr Pro Gln Lys Asp Ser Ser Arg Leu His Arg Pro Leu Ala Ile  
                   35                  40                  45  
 Ser Ala Val Leu Asn Ser Pro Val Asn Val Ala Pro Pro Ser Pro Glu  
                   50                  55                  60  
 Lys Thr Asp Lys Asn Lys Thr Phe Val Ser Arg Tyr Ala Pro Asp Glu  
   65                  70                  75                  80  
 Pro Arg Lys Gly Ala Asp Ile Leu Val Glu Ala Leu Glu Arg Gln Gly  
                   85                  90                  95

Val Glu Thr Val Phe Ala Tyr Pro Gly Gly Ala Ser Met Glu Ile His  
 100 105 110  
 Gln Ala Leu Thr Arg Ser Ser Thr Ile Arg Asn Val Leu Pro Arg His  
 115 120 125  
 Glu Gln Gly Gly Val Phe Ala Ala Glu Gly Tyr Ala Arg Ser Ser Gly  
 130 135 140  
 Lys Pro Gly Ile Cys Ile Ala Thr Ser Gly Pro Gly Ala Thr Asn Leu  
 145 150 155 160  
 Val Ser Gly Leu Ala Asp Ala Met Leu Asp Ser Val Pro Leu Val Ala  
 165 170 175  
 Ile Thr Gly Gln Val Pro Arg Arg Met Ile Gly Thr Asp Ala Phe Gln  
 180 185 190  
 Glu Thr Pro Ile Val Glu Val Thr Arg Ser Ile Thr Lys His Asn Tyr  
 195 200 205  
 Leu Val Met Asp Val Asp Asp Ile Pro Arg Ile Val Gln Glu Ala Phe  
 210 215 220  
 Phe Leu Ala Thr Ser Gly Arg Pro Gly Pro Val Leu Val Asp Val Pro  
 225 230 235 240  
 Lys Asp Ile Gln Gln Gln Leu Ala Ile Pro Asn Trp Asp Gln Pro Met  
 245 250 255  
 Arg Leu Pro Gly Tyr Met Ser Arg Leu Pro Gln Xaa Pro Glu Val Ser  
 260 265 270  
 Gln Leu Gly Gln Ile Val Arg Leu Ile Ser Glu Ser Lys Arg Pro Val  
 275 280 285  
 Leu Tyr Val Gly Gly Gly Ser Leu Asn Ser Ser Glu Glu Leu Gly Arg  
 290 295 300  
 Phe Val Glu Leu Thr Gly Ile Pro Val Ala Ser Thr Leu Met Gly Leu  
 305 310 315 320  
 Gly Ser Tyr Pro Cys Asn Asp Glu Leu Ser Leu Gln Met Leu Gly Met  
 325 330 335  
 His Gly Thr Val Tyr Ala Asn Tyr Ala Val Glu His Ser Asp Leu Leu  
 340 345 350  
 Leu Ala Phe Gly Val Arg Phe Asp Asp Arg Val Thr Gly Lys Leu Glu  
 355 360 365  
 Ala Phe Ala Ser Arg Ala Lys Ile Val His Ile Asp Ile Asp Ser Ala  
 370 375 380

Glu Ile Gly Lys Asn Lys Thr Pro His Val Ser Val Cys Gly Asp Val  
 385 390 395 400  
 Lys Leu Ala Leu Gln Gly Met Asn Lys Val Leu Glu Asn Arg Ala Glu  
 405 410 415  
 Glu Leu Lys Leu Asp Phe Gly Val Trp Arg Ser Glu Leu Ser Glu Gln  
 420 425 430  
 Lys Gln Lys Phe Pro Leu Ser Phe Lys Thr Phe Gly Glu Ala Ile Pro  
 435 440 445  
 Pro Gln Tyr Ala Ile Gln Ile Leu Asp Glu Leu Thr Glu Gly Lys Ala  
 450 455 460  
 Ile Ile Ser Thr Gly Val Gly Gln Arg Gln Met Trp Ala Ala Gln Phe  
 465 470 475 480  
 Tyr Lys Tyr Arg Lys Pro Arg Gln Trp Leu Ser Ser Ser Gly Leu Gly  
 485 490 495  
 Ala Met Gly Phe Gly Leu Pro Ala Ala Ile Gly Ala Ser Val Ala Asn  
 500 505 510  
 Pro Asp Ala Ile Val Val Asp Ile Asp Gly Asp Gly Ser Phe Ile Met  
 515 520 525  
 Asn Val Gln Glu Leu Ala Thr Ile Arg Val Glu Asn Leu Pro Val Lys  
 530 535 540  
 Ile Leu Leu Leu Asn Asn Gln His Leu Gly Met Val Met Gln Trp Glu  
 545 550 555 560  
 Asp Arg Phe Tyr Lys Ala Asn Arg Ala His Thr Tyr Leu Gly Asp Pro  
 565 570 575  
 Ala Arg Glu Asn Glu Ile Phe Pro Asn Met Leu Gln Phe Ala Gly Ala  
 580 585 590  
 Cys Gly Ile Pro Ala Ala Arg Val Thr Lys Lys Glu Glu Leu Arg Glu  
 595 600 605  
 Ala Ile Gln Thr Met Leu Asp Thr Pro Gly Pro Tyr Leu Leu Asp Val  
 610 615 620  
 Ile Cys Pro His Gln Glu His Val Leu Pro Met Ile Pro Asn Gly Gly  
 625 630 635 640  
 Thr Phe Lys Asp Val Ile Thr Glu Gly Asp Gly Arg Thr Lys Tyr  
 645 650 655

<210> 102  
 <211> 652  
 <212> PRT  
 <213> Brassica napus

<220>  
 <221> MOD\_RES  
 <222> (464)..(464)  
 <223> Variable amino acid

<400> 102  
 Met Ala Ala Ala Thr Ser Ser Ser Pro Ile Ser Leu Thr Ala Lys Pro  
 1 5 10 15  
 Ser Ser Lys Ser Pro Leu Pro Ile Ser Arg Phe Ser Leu Pro Phe Ser  
 20 25 30  
 Leu Thr Pro Gln Lys Pro Ser Ser Arg Leu His Arg Pro Leu Ala Ile  
 35 40 45  
 Ser Ala Val Leu Asn Ser Pro Val Asn Val Ala Pro Glu Lys Thr Asp  
 50 55 60  
 Lys Ile Lys Thr Phe Ile Ser Arg Tyr Ala Pro Asp Glu Pro Arg Lys  
 65 70 75 80  
 Gly Ala Asp Ile Leu Val Glu Ala Leu Glu Arg Gln Gly Val Glu Thr  
 85 90 95  
 Val Phe Ala Tyr Pro Gly Gly Ala Ser Met Glu Ile His Gln Ala Leu  
 100 105 110  
 Thr Arg Ser Ser Thr Ile Arg Asn Val Leu Pro Arg His Glu Gln Gly  
 115 120 125  
 Gly Val Phe Ala Ala Glu Gly Tyr Ala Arg Ser Ser Gly Lys Pro Gly  
 130 135 140  
 Ile Cys Ile Ala Thr Ser Gly Pro Gly Ala Thr Asn Leu Val Ser Gly  
 145 150 155 160  
 Leu Ala Asp Ala Met Leu Asp Ser Val Pro Leu Val Ala Ile Thr Gly  
 165 170 175  
 Gln Val Pro Arg Arg Met Ile Gly Thr Asp Ala Phe Gln Glu Thr Pro  
 180 185 190  
 Ile Val Glu Val Thr Arg Ser Ile Thr Lys His Asn Tyr Leu Val Met  
 195 200 205  
 Asp Val Asp Asp Ile Pro Arg Ile Val Gln Glu Ala Phe Phe Leu Ala  
 210 215 220



Thr Ser Gly Arg Pro Gly Pro Val Leu Val Asp Val Pro Lys Asp Ile  
 225 230 235 240  
 Gln Gln Gln Leu Ala Ile Pro Asn Trp Asp Gln Pro Met Arg Leu Pro  
 245 250 255  
 Gly Tyr Met Ser Arg Leu Pro Gln Pro Pro Glu Val Ser Gln Leu Gly  
 260 265 270  
 Gln Ile Val Arg Leu Ile Ser Glu Ser Lys Arg Pro Val Leu Tyr Val  
 275 280 285  
 Gly Gly Gly Ser Leu Asn Ser Ser Glu Glu Leu Gly Arg Phe Val Glu  
 290 295 300  
 Leu Thr Gly Ile Pro Val Ala Ser Thr Leu Met Gly Leu Gly Ser Tyr  
 305 310 315 320  
 Pro Cys Asn Asp Glu Leu Ser Leu Gln Met Leu Gly Met His Gly Thr  
 325 330 335  
 Val Tyr Ala Asn Tyr Ala Val Glu His Ser Asp Leu Leu Leu Ala Phe  
 340 345 350  
 Gly Val Arg Phe Asp Asp Arg Val Thr Gly Lys Leu Glu Ala Phe Ala  
 355 360 365  
 Ser Arg Ala Lys Ile Val His Ile Asp Ile Asp Ser Ala Glu Ile Gly  
 370 375 380  
 Lys Asn Lys Thr Pro His Val Ser Val Cys Gly Asp Val Lys Leu Ala  
 385 390 395 400  
 Leu Gln Gly Met Asn Lys Val Leu Glu Asn Arg Ala Glu Glu Leu Lys  
 405 410 415  
 Leu Asp Phe Gly Val Trp Arg Ser Glu Leu Ser Glu Gln Lys Gln Lys  
 420 425 430  
 Phe Pro Leu Ser Phe Lys Thr Phe Gly Glu Ala Ile Pro Pro Gln Tyr  
 435 440 445  
 Ala Ile Gln Val Leu Asp Glu Leu Thr Gln Gly Lys Ala Ile Ile Xaa  
 450 455 460  
 Thr Gly Val Gly Gln His Gln Met Trp Ala Ala Gln Phe Tyr Lys Tyr  
 465 470 475 480  
 Arg Lys Pro Arg Gln Trp Leu Ser Ser Ser Gly Leu Gly Ala Met Gly  
 485 490 495  
 Phe Gly Leu Pro Ala Ala Ile Gly Ala Ser Val Ala Asn Pro Asp Ala  
 500 505 510

Ile Val Val Asp Ile Asp Gly Asp Gly Ser Phe Ile Met Asn Val Gln  
515 520 525

Glu Leu Ala Thr Ile Arg Val Glu Asn Leu Pro Val Lys Ile Leu Leu  
530 535 540

Leu Asn Asn Gln His Leu Gly Met Val Met Gln Leu Glu Asp Arg Phe  
545 550 555 560

Tyr Lys Ala Asn Arg Ala His Thr Tyr Leu Gly Asp Pro Ala Arg Glu  
565 570 575

Asn Glu Ile Phe Pro Asn Met Leu Gln Phe Ala Gly Ala Cys Gly Ile  
580 585 590

Pro Ala Ala Arg Val Thr Lys Lys Glu Glu Leu Arg Glu Ala Ile Gln  
595 600 605

Thr Met Leu Asp Thr Pro Gly Pro Tyr Leu Leu Asp Ala Ile Cys Pro  
610 615 620

His Gln Glu His Val Leu Pro Met Ile Pro Ser Gly Gly Thr Phe Lys  
625 630 635 640

Asp Val Ile Thr Glu Gly Asp Gly Arg Thr Lys Tyr  
645 650

<210> 103

<211> 655

<212> PRT

<213> Brassica napus

<400> 103

Met Ala Ala Ala Thr Ser Ser Ser Pro Ile Ser Leu Thr Ala Lys Pro  
1 5 10 15

Ser Ser Lys Ser Pro Leu Pro Ile Ser Arg Phe Ser Leu Pro Phe Ser  
20 25 30

Leu Thr Pro Gln Lys Asp Ser Ser Arg Leu His Arg Pro Leu Ala Ile  
35 40 45

Ser Ala Val Leu Asn Ser Pro Val Asn Val Ala Pro Pro Ser Pro Glu  
50 55 60

Lys Thr Asp Lys Asn Lys Thr Phe Val Ser Arg Tyr Ala Pro Asp Glu  
65 70 75 80

Pro Arg Lys Gly Ala Asp Ile Leu Val Glu Ala Leu Glu Arg Gln Gly  
85 90 95

Val Glu Thr Val Phe Ala Tyr Pro Gly Gly Ala Ser Met Glu Ile His  
100 105 110

Gln Ala Leu Thr Arg Ser Ser Thr Ile Arg Asn Val Leu Pro Arg His  
 115 120 125

Glu Gln Gly Gly Val Phe Ala Ala Glu Gly Tyr Ala Arg Ser Ser Gly  
 130 135 140

Lys Pro Gly Ile Cys Ile Ala Thr Ser Gly Pro Gly Ala Thr Asn Leu  
 145 150 155 160

Val Ser Gly Leu Ala Asp Ala Met Leu Asp Ser Val Pro Leu Val Ala  
 165 170 175

Ile Thr Gly Gln Val Pro Arg Arg Met Ile Gly Thr Asp Ala Phe Gln  
 180 185 190

Glu Thr Pro Ile Val Glu Val Thr Arg Ser Ile Thr Lys His Asn Tyr  
 195 200 205

Leu Val Met Asp Val Asp Asp Ile Pro Arg Ile Val Gln Glu Ala Phe  
 210 215 220

Phe Leu Ala Thr Ser Gly Arg Pro Gly Pro Val Leu Val Asp Val Pro  
 225 230 235 240

Lys Asp Ile Gln Gln Gln Leu Ala Ile Pro Asn Trp Asp Gln Pro Met  
 245 250 255

Arg Leu Pro Gly Tyr Met Ser Arg Leu Pro Gln Pro Pro Glu Val Ser  
 260 265 270

Gln Leu Gly Gln Ile Val Arg Leu Ile Ser Glu Ser Lys Arg Pro Val  
 275 280 285

Leu Tyr Val Gly Gly Gly Ser Leu Asn Ser Ser Glu Glu Leu Gly Arg  
 290 295 300

Phe Val Glu Leu Thr Gly Ile Pro Val Ala Ser Thr Leu Met Gly Leu  
 305 310 315 320

Gly Ser Tyr Pro Cys Asn Asp Glu Leu Ser Leu Gln Met Leu Gly Met  
 325 330 335

His Gly Thr Val Tyr Ala Asn Tyr Ala Val Glu His Ser Asp Leu Leu  
 340 345 350

Leu Ala Phe Gly Val Arg Phe Asp Asp Arg Val Thr Gly Lys Leu Glu  
 355 360 365

Ala Phe Ala Ser Arg Ala Lys Ile Val His Ile Asp Ile Asp Ser Ala  
 370 375 380

Glu Ile Gly Lys Asn Lys Thr Pro His Val Ser Val Cys Gly Asp Val  
 385 390 395 400

Lys Leu Ala Leu Gln Gly Met Asn Lys Val Leu Glu Asn Arg Ala Glu  
 405 410 415  
 Glu Leu Lys Leu Asp Phe Gly Val Trp Arg Ser Glu Leu Ser Glu Gln  
 420 425 430  
 Lys Gln Lys Phe Pro Leu Ser Phe Lys Thr Phe Gly Glu Ala Ile Pro  
 435 440 445  
 Pro Gln Tyr Ala Ile Gln Ile Leu Asp Glu Leu Thr Glu Gly Lys Ala  
 450 455 460  
 Ile Ile Ser Thr Gly Val Gly Gln His Gln Met Trp Ala Ala Gln Phe  
 465 470 475 480  
 Tyr Lys Tyr Arg Lys Pro Arg Gln Trp Leu Ser Ser Ser Gly Leu Gly  
 485 490 495  
 Ala Met Gly Phe Gly Leu Pro Ala Ala Ile Gly Ala Ser Val Ala Asn  
 500 505 510  
 Pro Asp Ala Ile Val Val Asp Ile Asp Gly Asp Gly Ser Phe Ile Met  
 515 520 525  
 Asn Val Gln Glu Leu Ala Thr Ile Arg Val Glu Asn Leu Pro Val Lys  
 530 535 540  
 Ile Leu Leu Leu Asn Asn Gln His Leu Gly Met Val Met Gln Trp Glu  
 545 550 555 560  
 Asp Arg Phe Tyr Lys Ala Asn Arg Ala His Thr Tyr Leu Gly Asp Pro  
 565 570 575  
 Ala Arg Glu Asn Glu Ile Phe Pro Asn Met Leu Gln Phe Ala Gly Ala  
 580 585 590  
 Cys Gly Ile Pro Ala Ala Arg Val Thr Lys Lys Glu Glu Leu Arg Glu  
 595 600 605  
 Ala Ile Gln Thr Met Leu Asp Thr Pro Gly Pro Tyr Leu Leu Asp Val  
 610 615 620  
 Ile Cys Pro His Gln Glu His Val Leu Pro Met Ile Pro Ser Gly Gly  
 625 630 635 640  
 Thr Phe Lys Asp Val Ile Thr Glu Gly Asp Gly Arg Thr Lys Tyr  
 645 650 655

&lt;210&gt; 104

&lt;211&gt; 652

&lt;212&gt; PRT

&lt;213&gt; Brassica napus

&lt;400&gt; 104

Met Ala Ala Ala Thr Ser Pro Ser Pro Ile Ser Leu Thr Ala Lys Pro  
 1 5 10 15  
 Ser Ser Lys Ser Pro Leu Pro Ile Ser Arg Phe Ser Leu Pro Phe Ser  
 20 25 30  
 Leu Thr Pro Gln Lys Pro Ser Ser Arg Leu His Arg Pro Leu Ala Ile  
 35 40 45  
 Ser Ala Val Leu Asn Ser Pro Val Asn Val Ala Pro Glu Lys Thr Asp  
 50 55 60  
 Lys Ile Lys Thr Phe Ile Ser Arg Tyr Ala Pro Asp Glu Pro Arg Lys  
 65 70 75 80  
 Gly Ala Asp Ile Leu Val Glu Ala Leu Glu Arg Gln Gly Val Glu Thr  
 85 90 95  
 Val Phe Ala Tyr Pro Gly Gly Ala Ser Met Glu Ile His Gln Ala Leu  
 100 105 110  
 Thr Arg Ser Ser Thr Ile Arg Asn Val Leu Pro Arg His Glu Gln Gly  
 115 120 125  
 Gly Val Phe Ala Ala Glu Gly Tyr Ala Arg Ser Ser Gly Lys Pro Gly  
 130 135 140  
 Ile Cys Ile Ala Thr Ser Gly Pro Gly Ala Thr Asn Leu Val Ser Gly  
 145 150 155 160  
 Leu Ala Asp Ala Met Leu Asp Ser Val Pro Leu Val Ala Ile Thr Gly  
 165 170 175  
 Gln Val Pro Arg Arg Met Ile Gly Thr Asp Ala Phe Gln Glu Thr Pro  
 180 185 190  
 Ile Val Glu Val Thr Arg Ser Ile Thr Lys His Asn Tyr Leu Val Met  
 195 200 205  
 Asp Val Asp Asp Ile Pro Arg Ile Val Gln Glu Ala Phe Phe Leu Ala  
 210 215 220  
 Thr Ser Gly Arg Pro Gly Pro Val Leu Val Asp Val Pro Lys Asp Ile  
 225 230 235 240  
 Gln Gln Gln Leu Ala Ile Pro Asn Trp Asp Gln Pro Met Arg Leu Pro  
 245 250 255  
 Gly Tyr Met Ser Arg Leu Pro Gln Pro Pro Glu Val Ser Gln Leu Gly  
 260 265 270

Gln Ile Val Arg Leu Ile Ser Glu Ser Lys Arg Pro Val Leu Tyr Val  
 275 280 285

Gly Gly Gly Ser Leu Asn Ser Ser Glu Glu Leu Gly Arg Phe Val Glu  
 290 295 300

Leu Thr Gly Ile Pro Val Ala Ser Thr Leu Met Gly Leu Gly Ser Tyr  
 305 310 315 320

Pro Cys Asn Asp Glu Leu Ser Leu Gln Met Leu Gly Met His Gly Thr  
 325 330 335

Val Tyr Ala Asn Tyr Ala Val Glu His Ser Asp Leu Leu Leu Ala Phe  
 340 345 350

Gly Val Arg Phe Asp Asp Arg Val Thr Gly Lys Leu Glu Ala Phe Ala  
 355 360 365

Ser Arg Ala Lys Ile Val His Ile Asp Ile Asp Ser Ala Glu Ile Gly  
 370 375 380

Lys Asn Lys Thr Pro His Val Ser Val Cys Gly Asp Val Lys Leu Ala  
 385 390 395 400

Leu Gln Gly Met Asn Lys Val Leu Glu Asn Arg Ala Glu Glu Leu Lys  
 405 410 415

Leu Asp Phe Gly Val Trp Arg Ser Glu Leu Ser Glu Gln Lys Gln Lys  
 420 425 430

Phe Pro Leu Ser Phe Lys Thr Phe Gly Glu Ala Ile Pro Pro Gln Tyr  
 435 440 445

Ala Ile Gln Val Leu Asp Glu Leu Thr Gln Gly Lys Ala Ile Ile Ser  
 450 455 460

Thr Gly Val Gly Gln His Gln Met Trp Ala Ala Gln Phe Tyr Lys Tyr  
 465 470 475 480

Arg Lys Pro Arg Gln Trp Leu Ser Ser Ser Gly Leu Gly Ala Met Gly  
 485 490 495

Phe Gly Leu Pro Ala Ala Ile Gly Ala Ser Val Ala Asn Pro Asp Ala  
 500 505 510

Ile Val Val Asp Ile Asp Gly Asp Gly Ser Phe Ile Met Asn Val Gln  
 515 520 525

Glu Leu Ala Thr Ile Arg Val Glu Asn Leu Pro Val Lys Ile Leu Leu  
 530 535 540

Leu Asn Asn Gln His Leu Gly Met Val Met Gln Trp Glu Asp Arg Phe  
 545 550 555 560



<210> 108  
 <211> 10  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 108

Ile Pro Asn Gly Gly Thr Phe Lys Asp Val  
 1 5 10

<210> 109  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 109

atcccaaatg gtggcacttt caaagatgta

30

<210> 110  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 110

catctttgaa agtgccacca t

21

<210> 111  
 <211> 10  
 <212> PRT  
 <213> Brassica napus

<400> 111

Met Gln Trp Glu Asp Arg Phe Tyr Lys Ala  
 1 5 10

<210> 112  
 <211> 30  
 <212> DNA  
 <213> Brassica napus



<400> 112  
atgcaatggg aagatcgggt ctacaaagct

30

<210> 113  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 113  
ctttgtagaa ccgatcttcc c

21

<210> 114  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 114  
Met Gln Leu Glu Asp Arg Phe Tyr Lys Ala  
1 5 10

<210> 115  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 115  
atgcaattgg aagatcgggt ctacaaagct

30

<210> 116  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 116  
ctttgtagaa ccgatcttcc a

21

**CLAIMS**

1. A method of assaying a plant for imidazolinone herbicide resistance conferred by the combination of a PM1 mutation of a *B. napus AHAS1* gene and a PM2 mutation of a *B. napus AHAS3* gene, the method comprising the steps of:

- a) isolating genomic DNA from the plant;
- b) determining the presence or absence of the PM1 mutation in the DNA; and
- c) determining the presence or absence of the PM2 mutation in the DNA,

wherein the presence of the PM1 mutation and the PM2 mutation is indicative of commercially relevant imidazolinone tolerance in the plant.

2. The method of claim 1, wherein the plant is a *Brassica* species.

3. The method of claim 2, wherein the *Brassica* species is selected from the group consisting of *B. napus*, *B. campestris/rapa*, and *B. juncea*.

4. The method of claim 1, further comprising the step of amplifying the isolated DNA prior to determining the presence or absence of the PM1 and PM2 mutations.

5. The method of claim 1, wherein the determining steps are performed using a primer extension-based single nucleotide polymorphism detection method.

6. A PM1 primer extension oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO: 13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO: 19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26; SEQ ID NO:27; SEQ ID NO: 28; SEQ ID NO:29; SEQ ID No;30; SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:39; SEQ ID NO:40; SEQ ID NO:41; SEQ ID NO:42 and SEQ ID NO:95.

7. A PM1 oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:46.

8. A PM2 primer extension oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:47; SEQ ID NO:48; SEQ ID NO:49; SEQ ID NO:50; SEQ ID NO:51; SEQ ID NO:52; SEQ ID NO:53; SEQ ID NO:54; SEQ ID NO:55; SEQ ID NO:56; SEQ ID NO:57; SEQ ID NO:58; SEQ ID NO:59; SEQ ID NO:60; SEQ ID NO:61; SEQ ID NO:62; SEQ ID NO:63; SEQ ID NO:64; SEQ ID NO:65; SEQ ID NO:66; SEQ ID NO:67; SEQ ID NO:68; SEQ ID NO:69; SEQ ID NO:70; SEQ ID NO:71; SEQ ID NO:72; SEQ ID NO:73; SEQ ID NO:74; SEQ ID NO:75; SEQ ID NO:76; SEQ ID NO:77; SEQ ID NO:78; SEQ ID NO:79; SEQ ID NO:80; SEQ ID NO:81; SEQ ID NO:82; SEQ ID NO:83; SEQ ID NO:84 and SEQ ID NO:96.

9. A PM2 oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:87 and SEQ ID NO:88.

10. An oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:43; SEQ ID NO:44; SEQ ID NO:85 and SEQ ID NO:86.

11. An amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:90; SEQ ID NO:91; SEQ ID NO:92; SEQ ID NO:93; and SEQ ID NO:94.

**PM1-AHAS1 nucleotide sequence(SEQ ID NO: 1) and  
translated amino acid sequence (SEQ ID NO: 101)**

1 TCATCATCTCTCTCTCTCAAACCATGGCGGGCGCAACATCGTCTTCTCCGATCTCCTTAACCGCTAAACCTTCTTCAAATCCCCTCTACCCATTCCA  
M A A A T S S S P I S L T A K P S S K S P L P I S

101 GATTCTCCCTTCCCTTCTCCTTAACCCACAGAAAGACTCCTCCCGTCTCCACCGTCTCTCGCCATCTCCGCCGTTCTCAACTACCCGTCATGTCCG  
R F S L P F S L T P Q K D S S R L H R P L A I S A V L N S P V N V A

201 ACCTCCTTCCCCTGAAAAACCGACAAGAACAAGACTTTCGTCTCCCGCTACGCTCCCGACGAGCCCCGAAGGGTGCTGATATCCTCGTCGAAGCCCTC  
P P S P E K T D K N K T F V S R Y A P D E P R K G A D I L V E A L

301 GAGCGTCAAGGCGTCGAAACCGTCTTTGCTTATCCCGGAGGTGCTTCCATGGAGATCCACCAAGCCTTGACTCGCTCCTCCACCATCCGTAACGTCCTTC  
E R Q G V E T V F A Y P G G A S M E I H Q A L T R S S T I R N V L

401 CCCGTCACGAACAAGGAGGAGTCTTCGCCGCGAGGGTTACGCTCGTTCCTCCGGCAAACCGGAATCTGCATAGCCACTTCGGGTCCCGGAGCTACCAA  
P R H E Q G G V F A A E G Y A R S S G K P G I C I A T S G P G A T N

501 CCTCGTCAGCGGGTTAGCAGACGCGATGCTTGACAGTGTTCCTCTTGTGCCATTACAGGACAGGTCCTCGCCGGATGATCGGTACTGACGCCTTCCAA  
L V S G L A D A M L D S V P L V A I T G Q V P R R M I G T D A F Q

601 GAGACCCAATCGTTGAGGTAACGAGGTCTATTACGAAACATAACTATCTGGTGATGGATGTTGATGACATACCTAGGATCGTTCAAGAAGCATTCCTTC  
E T P I V E V T R S I T K H N Y L V M D V D D I P R I V Q E A F F

701 TAGCTACTTCCGGTAGACCCGGACCGGTTTTGGTTGATGTTCTAAGGATATTCAGCAGCAGCTTGGGATTCCTAACTGGGATCAACCTATGCGCTTGCC  
L A T S G R P G P V L V D V P K D I Q Q Q L A I P N W D Q P M R L P

801 TGGCTACATGTCTAGGTTGCCCTCAGCCWCCGGAAGTTTCTCAGTTAGGTCAGATCGTTAGGTTGATCTCGGAGTCTAAGAGGCCTGTTTTGTACGTTGGT  
G Y M S R L P Q X P E V S Q L G Q I V R L I S E S K R P V L Y V G

901 GGTGGAAGCTTGAACCTCGAGTGAAGAAGTGGGGAGATTTGTCGAGCTTACTGGGATCCCTGTTGCGAGTACGTTGATGGGGCTTGGCTCTTATCCTTGTA  
G G S L N S S E E L G R F V E L T G I P V A S T L M G L G S Y P C

1001 ACGATGAGTTGTCCTGCAGATGCTTGGCATGCACGGGACTGTGTATGCTAACTACGCTGTGGAGCATAGTGATTTGTTGCTGGCGTTTGGTGTAGGTT  
N D E L S L Q M L G M H G T V Y A N Y A V E H S D L L L A F G V R F

1101 TGATGACCGTGTACGGGAAAGCTCGAGGCTTTCGCTAGCAGGGCTAAAATTGTGCACATAGACATTGATTTCTGCTGAGATTGGGAAGAATAAGACACCT  
D D R V T G K L E A F A S R A K I V H I D I D S A E I G K N K T P

1201 CACGTGTCTGTGTGGTGTGTAAGCTGGCTTTCGAAGGGATGAACAAGGTTCTTGAGAACC GGCGGAGGAGCTCAAGCTTGATTTCCGGTGTGGTGA  
H V S V C G D V K L A L Q G M N K V L E N R A E E L K L D F G V W

1301 GGAGTGAGTTGAGCGAGCAGAAACAGAAGTTCCTTTGAGCTTCAAACGTTTGGAGAAGCCATTCTCCGCAGTACCGGATTCAGATCCTCGACGAGCT  
R S E L S E Q K Q K F P L S F K T F G E A I P P Q Y A I Q I L D E L

1401 AACCGAAGGGAAGGCAATTATCAGTACTGGTGTGGACAGCGTCAGATGTGGGCGGCGAGTTTTACAAGTACAGGAAGCCGAGACAGTGGCTGTCTGCA  
T E G K A I I S T G V G Q R Q M W A A Q F Y K Y R K P R Q W L S S

1501 TCAGGCCTCGGAGCTATGGGTTTTGGACTTCTGCTGCGATTGGAGCGTCTGTGGCGAACCCCTGATGCGATTGTTGTGGATATTGACGGTGATGGAAGCT  
S G L G A M G F G L P A A I G A S V A N P D A I V V D I D G D G S

1601 TCATAATGAACGTTCAAGAGCTGGCCACAATCCGTGTAGAGAATCTTCTGTGAAGATACTCTTGTAAACAACCAGCATCTTGGGATGGTCATGCAATG  
F I M N V Q E L A T I R V E N L P V K I L L L N N Q H L G M V M Q W

1701 GGAAGATCGGTTCTACAAAGCTAACAGAGCTCACACTTATCTCGGGGACCCGGCAAGGGAGAACGAGATCTTCCCTAACATGCTGCAGTTTGCAGGAGCT  
E D R F Y K A N R A H T Y L G D P A R E N E I F P N M L Q F A G A

1801 TCGGGATTCCAGCTGCGAGAGTGACGAAGAAAGAAGAACTCCGAGAAGCTATTCAGACAATGCTGGATACACCAGGACCATACTGTTGGATGTGATAT  
C G I P A A R V T K K E E L R E A I Q T M L D T P G P Y L L D V I

1901 GTCCGCACCAAGAACATGTGTTACCGATGATCCCAATGGTGGCACTTTCAAAGATGTAATAACAGAAGGGGATGGTCGCACTAAGTACTGAGAGATTMA  
C P H Q E H V L P M I P N G G T F K D V I T E G D G R T K Y

2001 GCTGGTGATCGATCATATGGTAAAAGACTTAGTTTCAGTTTCCAGTTTCTTTTGTGTGGTAATTTGGGTTTGTGAGTTGTTGT

**FIG. 1A**

**PM2-AHAS3 nucleotide sequence (SEQ ID NO:2) and  
translated amino acid sequence (SEQ ID NO: 102)**

1 TTCATCATMTCTCTCATTCTCTCTCTCTCTCATCTAACCATGGCGGGCAACATCGTCTTCTCCGATCTCCTTAACCGCTAAACCTTCTTCCAAT  
M A A A T S S S P I S L T A K P S S K

101 CCCCTTACCCATTTCCAGATTCTCCCTTCCCTTCTCCTTAACCCACAGAAACCTCCTCCCGTCTCCACCGTCCACTCGCCATCTCCGCCGTTCTCAA  
S P L P I S R F S L P F S L T P Q K P S S R L H R P L A I S A V L N

201 CTCACCCGTC AATGTCGCACCTGAAAAACCGACAAGATCAAGACTTTTCATCTCCCGCTACGCTCCCGACGAGCCCCGCAAGGGTGTGATATCCTCGTG  
S P V N V A P E K T D K I K T F I S R Y A P D E P R K G A D I L V

301 GAAGCCCTCGAGCGTCAAGGCGTCGAAACCGTCTTCGCTTATCCCGGAGGTGCCTCCATGGAGATCCACCAAGCCTTGACTCGCTCCTCCACCATCCGTA  
E A L E R Q G V E T V F A Y P G G A S M E I H Q A L T R S S T I R

401 ACGTCTCCCGTACGCAACAAGGAGGAGTCTTCGCCCGGAGGGTACGCTCGTTCCTCCGGCAAACCGGGAATCTGCATAGCCACTTCGGGTCCCGG  
N V L P R H E Q G G V F A A E G Y A R S S G K P G I C I A T S G P G

501 AGCTACCAACCTCGTCAGCGGGTTAGCCGACGCGATGCTTGACAGTGTTCCTCTCGTCGCCATCACAGGACAGGTCCCTCGCCGGATGATCGGTACTGAC  
A T N L V S G L A D A M L D S V P L V A I T G Q V P R R M I G T D

601 GCGTTC AAGAGACGCCAATCGTTGAGGTAACGAGGTCTATTACGAAACATAACTATCTGGTGATGGATGTTGATGACATACCTAGGATCGTTCAAGAAG  
A F Q E T P I V E V T R S I T K H N Y L V M D V D D I P R I V Q E

701 CATTCTTTCTAGCTACTTCCGGTAGACCCGGACCGGTTTTGGTTGATGTTCTTAAGGATATTCAGCAGCAGCTTGGGATTCCTAACTGGGATCAACCTAT  
A F F L A T S G R P G P V L V D V P K D I Q Q Q L A I P N W D Q P M

801 GCGCTTGCCTGGCTACATGTCTAGGCTGCCTCAGCCACCGGAAGTTTCTCAGTTAGCCAGATCGTTAGGTTGATCTCGGAGTCTAAGAGGCCTGTTTTG  
R L P G Y M S R L P Q P P E V S Q L G Q I V R L I S E S K R P V L

901 TACGTTGGTGGTGAAGCTTGAAGCTCGAGTGAAGAACTGGGGAGATTTGTCGAGCTTACTGGGATCCCTGTTGCGAGTACGCTGATGGGGCTTGGCTCTT  
Y V G G G S L N S S E E L G R F V E L T G I P V A S T L M G L G S

1001 ATCCTTGTAACGATGAGTTGTCCTGCAGATGCTTGGCATGCACGGGACTGTGTATGCTAACTACGCTGTGGAGCATAGTGATTTGTTGCTGGCGTTTGG  
Y P C N D E L S L Q M L G M H G T V Y A N Y A V E H S D L L L A F G

1101 TGTTAGGTTTGTGACCGTGTACCGGAAAGCTCGAGGCGTTTTGCGAGCAGGGCTAAGATTGTGCACATAGACATTGATTCTGCTGAGATTGGGAAGAAT  
V R F D D R V T G K L E A F A S R A K I V H I D I D S A E I G K N

1201 AAGACACCTCACGTGTCTGTGTGGTGTGATGTAAGCTGGCTTTGCAAGGGATGAACAAGGTTCTTGAGAACCGGGCGGAGGAGCTCAAGCTTGATTTCCG  
K T P H V S V C G D V K L A L Q G M N K V L E N R A E E L K L D F

1301 GTGTTTGGAGGAGTGAGTTGAGCGAGCAGAAACAGAAGTTCCCGTTGAGCTTCAAACGTTTGGAGAAGCCATTCTCCGAGTACGCGATTACAGGTCTCT  
G V W R S E L S E Q K Q K F P L S F K T F G E A I P P Q Y A I Q V L

1401 AGACGAGCTAACCAAGGGAAGGCAATTATCAGNACTGGTGTGGACAGCATCAGATGTGGGCGGCGAGTTTTACAAGTACAGGAAGCCGAGGCAGTGG  
D E L T Q G K A I I X T G V G Q H Q M W A A Q F Y K Y R K P R Q W

1501 CTGTCGTCCTCAGGACTCGGAGCTATGGGTTTCCGACTTCTGCTGCGATTGGAGCGTCTGTGGCGAACCTGATGCGATTGTTGTGGACATTGACGGTG  
L S S S G L G A M G F G L P A A I G A S V A N P D A I V V D I D G

1601 ATGGAAGCTTCATAATGAACGTTCAAGAGCTGGCCACAATCCGTGTAGAGAATCTTCCCTGTGAAGATACTCTTGTTAAACAACCAGCATCTTGGGATGGT  
D G S F I M N V Q E L A T I R V E N L P V K I L L L N N Q H L G M V

1701 CATGCAATTTGAAGATCGGTTCTACAAAGCTAACAGAGCTCACACTTATCTCGGGACCCGGCAAGGGAGAACGAGATCTTCCCTAACATGCTGCAGTTT  
M Q L E D R F Y K A N R A H T Y L G D P A R E N E I F P N M L Q F

1801 GCAGGAGCTTGGCGGATTCCAGCTGCGAGAGTGACGAAGAAAGAAGAACTCCGAGAAGCTATTCAGACAATGCTGGATAACCTGGACCGTACCTGTTGG  
A G A C G I P A A R V T K K E E L R E A I Q T M L D T P G P Y L L

1901 ATGCCATCTGTCCGCACCAAGAACATGTGTTACCGATGATCCCAAGTGGTGGCACTTTCAAAGATGTAATAACCGAAGGGGATGGTCGCACTAAGTACTG  
D A I C P H Q E H V L P M I P S G G T F K D V I T E G D G R T K Y

2001 AGAGATGAAGCTGGTGTATCCATCGTATGGTAAAAGACTTAGTTTTCAGTTTTTTCAGTTTTCTTTTGTGTGGTAATTTGGGTTTGTGAGTTGTTGTTTGTCTT

2101 TGGTTTGTCCCNKAC

**FIG. 1B**

**T-AHAS1 nucleotide sequence (SEQ ID NO:3) and  
translated amino acid sequence (SEQ ID NO: 103)**

1 TCATCATCTCTCTCTCTCTAACCATGGCGGGCAACATCGTCTTCTCCGATCTCCTTAACCGCTAAACCTTCTTCCAATCCCCTCTACCCATTCCA  
M A A A T S S S P I S L T A K P S S K S P L P I S

101 GATTCTCCCTTCCCTTCTCTTAACCCACAGAAAGACTCCTCCCGTCTCCACCGTCTCTCGCCATCTCCGCCGTTCTCAACTCACCCGTCAATGTCGC  
R F S L P F S L T P Q K D S S R L H R P L A I S A V L N S P V N V A

201 ACCTCCTTCCCCTGAAAAACCGACAAGAACAAGACTTTCGTCTCCCGCTACGCTCCCGACGAGCCCCGCAAGGGTGCTGATATCCTCGTGAAGCCCTC  
P P S P E K T D K N K T F V S R Y A P D E P R K G A D I L V E A L

301 GAGCGTCAAGGCGTCAAACCGTCTTTGCTTATCCCGGAGGTGCTTCCATGGAGATCCACCAAGCCTTGACTCGCTCCTCCACCATCCGTAACGTCCTTC  
E R Q G V E T V F A Y P G G A S M E I H Q A L T R S S T I R N V L

401 CCCGTCACGAACAAGGAGGAGTCTTCGCCGCCGAGGGTTACGCTCGTTCCTCCGGCAAACCGGGAATCTGCATAGCCACTTCGGGTCCCGGAGCTACCAA  
P R H E Q G G V F A A E G Y A R S S G K P G I C I A T S G P G A T N

501 CCTCGTCAGCGGGTTAGCAGACGGATGCTTGACAGTGTTCCTTGTGCGCCATTACAGGACAGGTCCCTCGCCGGATGATCGGTACTGACGCCTTCCAA  
L V S G L A D A M L D S V P L V A I T G Q V P R R M I G T D A F Q

601 GAGACACCAATCGTTGAGGTAACGAGGTCTATTACGAAACATAACTATTTGGTGATGGATGTTGATGACATACCTAGGATCGTTCAAGAAGCTTTCTTTC  
E T P I V E V T R S I T K H N Y L V M D V D D I P R I V Q E A F F

701 TAGCTACTTCCGGTAGACCCGACCGGTTTGGTTGATGTTCTTAAGGATATTCAGCAGCAGCTTGGGATTCCTAACTGGGATCAACCTATGCGCTTACC  
L A T S G R P G P V L V D V P K D I Q Q Q L A I P N W D Q P M R L P

801 TGGCTACATGTCTAGGTTGCCTCAGCCTCCGGAAGTTTCTCAGTTAGGTCAGATCGTTAGGTTGATCTCGGAGTCTAAGAGGCCTGTTTTGTACGTTGGT  
G Y M S R L P Q P P E V S Q L G Q I V R L I S E S K R P V L Y V G

901 GGTGGAAGCTTGAACCTCAGTGAAGAAGTGGGAGATTTGTGCGAGCTTACTGGGATCCCGTTCGAGTACTTTGATGGGGCTTGGCTCTTATCCTTGTA  
G G S L N S S E E L G R F V E L T G I P V A S T L M G L G S Y P C

1001 ACCGATGAGTTGTCCCTGCAGATGCTTGGCATGCACGGGACTGTGTATGCTAACTACGCTGTGGAGCATAGTGATTTGTTGCTGGCGTTTGGTGTAGGTT  
N D E L S L Q M L G M H G T V Y A N Y A V E H S D L L L A F G V R F

1101 TGATGACCGTGTACGGGAAAGCTCGAGGCTTTCGCTAGCAGGGCTAAAATTGTGCACATAGACATTGATTTCTGCTGAGATTGGGAAGAATAAGACACCT  
D D R V T G K L E A F A S R A K I V H I D I D S A E I G K N K T P

1201 CACGTGTCTGTGTGGTGTGATGTAAGCTGGCTTTGCAAGGGATGAACAAGGTTCTTGAGAACC GGCGGAGGAGCTCAAGCTTGATTTCCGGTGTGGTA  
H V S V C G D V K L A L Q G M N K V L E N R A E E L K L D F G V W

1301 GGAGTGAGTTGAGCGAGCAGAAACAGAAGTCCCTTTGAGCTTCAAACGTTTGGAGAAGCCATTCCCTCCGCAGTACCGGATTCAGATCCTCGACGAGCT  
R S E L S E Q K Q K F P L S F K T F G E A I P P Q Y A I Q I L D E L

1401 AACCGAAGGGAAGCAATTATCAGTACTGGTGTGGACAGCATCAGATGTGGCGGCGCAGTTTTACAAGTACAGGAAGCCGAGACAGTGGCTGTCTGCA  
T E G K A I I S T G V G Q H Q M W A A Q F Y K Y R K P R Q W L S S

1501 TCAGGCCTCGGAGCTATGGGTTTTGGACTTCCCTGCTGCGATTGGAGCGTCTGTGGCGAACCCCTGATGCGATTGTTGTGGATATTGACGGTGATGGAAGCT  
S G L G A M G F G L P A A I G A S V A N P D A I V V D I D G D G S

1601 TCATAATGAACGTTCAAGAGCTGGCCACAATCCGTGTAGAGAATCTTCCCTGTGAAGATACTCTTGTAAACAACCAGCATCTTGGGATGGTCATGCAATG  
F I M N V Q E L A T I R V E N L P V K I L L L N N Q H L G M V M Q W

1701 GGAAGATCGGTTCTACAAAGCTAACAGAGCTCACACTTATCTCGGGGACCCGCAAGGGAGAACCAGATCTTCCCTAACATGCTGCAGTTTGCAGGAGCT  
E D R F Y K A N R A H T Y L G D P A R E N E I F P N M L Q F A G A

1801 TGCGGGATTCCAGCTGCGAGAGTGACGAAGAAGAAGACTCCGAGAAGCTATTTCAGACAATGCTGGATACACCAGGACCATACCTGTTGGATGTGATAT  
C G I P A A R V T K K E E L R E A I Q T M L D T P G P Y L L D V I

1901 GTCCGCACCAAGAACATGTGTTACCGATGATCCAAGTGGTGGCACTTCAAAGATGTAATAACAGAAGGGGATGGTGCCTAAGTACTGAGAGATGAA  
C P H Q E H V L P M I P S G G T F K D V I T E G D G R T K Y

2001 GCTGGTGTGATCATATGGTAAAAGACTTAGTTTCAGTTTCCAGTTTCTTTTGTGGTAATTTGGGTTTGTGAGTTGTTGT

**FIG. 1C**

**T-AHAS3 (SEQ ID NO: 4) nucleotide sequence and  
translated amino acid sequence (SEQ ID NO: 104)**

1 TTMMACATCTCTCTCATTNCACTCTCTCCCTCATCTAACCATGGCGGCGGCAACATCGCCTTCTCCGATCTCCTTAACCGCTAAACCTTCTTCCAAT  
M A A A T S P S P I S L T A K P S S K

101 CCCCTCTACCCATTTCCAGATTCTCCCTTCCCTTCTCCTTAACCCACAGAAACCTCCTCCCGTCTCCACCGTCCACTCGCCATCTCCGCCGTTCTCAA  
S P L P I S R F S L P F S L T P Q K P S S R L H R P L A I S A V L N

201 CTCACCCGTCAATGTCGCACCTGAAAAACCGACAAGATCAAGACTTTCATCTCCCGCTACGCTCCCGACGAGCCCCGCAAGGGTGCTGATATCCTCGTG  
S P V N V A P E K T D K I K T F I S R Y A P D E P R K G A D I L V

301 GAAGCCCTCGAGCGTCAAGGCGTCAAACCGTCTTCGCTTATCCCGGAGGTGCCTCCATGGAGATCCACCAAGCCTTGACTCGCTCCTCCACCATCCGTA  
E A L E R Q G V E T V F A Y P G G A S M E I H Q A L T R S S T I R

401 ACGTCTCCCCCGTACGAACAAGGAGGAGTCTTCGCCGCCGAGGGTTACGCTCGTTCCTCCGGCAAACCGGGAATCTGCATAGCCACTTCGGGTCCCGG  
N V L P R H E Q G G V F A A E G Y A R S S G K P G I C I A T S G P G

501 AGCTACCAACCTCGTCAGCGGGTTAGCCGACGCGATGCTTGACAGTGTTCCTCTCGTCGCCATCACAGGACAGGTCCTCGCCGGATGATCGGTACTGAC  
A T N L V S G L A D A M L D S V P L V A I T G Q V P R R M I G T D

601 GCGTCCAAGAGACGCCAATCGTTGAGGTAACGAGGTCATTACGAAACATAACTATCTGGTGATGGATGTTGATGACATACCTAGGATCGTTCAAGAAG  
A F Q E T P I V E V T R S I T K H N Y L V M D V D D I P R I V Q E

701 CATCTTTCTAGCTACTTCCGGTAGACCCGGACCGGTTTTGGTTGATGTTCCCTAAGGATATTCAGCAGCAGCTTGGGATTCCTAACTGGGATCAACCTAT  
A F F L A T S G R P G P V L V D V P K D I Q Q Q L A I P N W D Q P M

801 GCGCTTGCCTGGCTACATGTCTAGGCTGCCTCAGCCACCGGAAGTTTCTCAGTTAGGCCAGATCGTTAGGTTGATCTCGGAGTCTAAGAGGCCTGTTTTG  
R L P G Y M S R L P Q P P E V S Q L G Q I V R L I S E S K R P V L

901 TACGTTGGTGGTGAAGCTTGAACCTCGAGTGAGGAAGTGGGAGATTTGTCGAGCTTACTGGGATCCCTGTTGCGAGTACGTTGATGGGGCTTGGCTCTT  
Y V G G G S L N S S E E L G R F V E L T G I P V A S T L M G L G S

1001 ATCCTTGTAACGATGAGTTGTCCCTGCAGATGCTTGGCATGCACGGGACTGTGTATGCTAACTACGCTGTGGAGCATAGTGATTTGTTGCTGGCGTTTGG  
Y P C N D E L S L Q M L G M H G T V Y A N Y A V E H S D L L L A F G

1101 TGTTAGGTTTGTGACCGTGTACGGGAAAGCTCGAGGCGTTTTCGAGCAGGGCTAAGATTGTGCACATAGACATTGATTCTGCTGAGATTGGGAAGAAT  
V R F D D R V T G K L E A F A S R A K I V H I D I D S A E I G K N

1201 AAGACACCTCACGTGTCTGTGTGGTGTGTAAGCTGGCTTTGCAAGGGATGAACAAGGTTCTTGAGAACCAGGGCGGAGGAGCTCAAGCTTGATTTCG  
K T P H V S V C G D V K L A L Q G M N K V L E N R A E E L K L D F

1301 GTGTTTGGAGGAGTGAGTTGAGCGAGCAGAAACAGAAGTCCCGTTGAGCTTCAAACGTTTGGAGAAGCCATTCCCTCCGCAGTACCGGATTCAGTCCCT  
G V W R S E L S E Q K Q K F P L S F K T F G E A I P P Q Y A I Q V L

1401 AGACGAGCTAACCCAAGGAAGCAATTATCAGTACTGGTGTGGACAGCATCAGATGTGGGCGGCGAGTTTTACAAGTACAGGAAGCCGAGGAGCTGG  
D E L T Q G K A I I S T G V G Q H Q M W A A Q F Y K Y R K P R Q W

1501 CTGTCGCTCAGGACTCGGAGCTATGGGTTTCCGACTTCCCTGCTGCGATTGGAGCGTCTGTGGCGAACCTGATGCGATTGTTGTGGACATTGACGGTG  
L S S S G L G A M G F G L P A A I G A S V A N P D A I V V D I D G

1601 ATGGAAGCTTCATAATGAACGTTCAAGAGCTGGCCACAATCCGTGTAGAGAATCTTCTGTGAAGATACTCTTGTAAACAACCAGCATCTTGGGATGGT  
D G S F I M N V Q E L A T I R V E N L P V K I L L L N N Q H L G M V

1701 CATGCAATGGGAAGATCGGTTCTACAAAGCTAACAGAGCTCACACTTATCTCGGGGACCCGCAAGGGAGAACGAGATCTTCCCTAACATGCTGCAGTTT  
M Q W E D R F Y K A N R A H T Y L G D P A R E N E I F P N M L Q F

1801 GCAGGAGCTTGGGGATTCCAGCTGCGAGAGTGACGAAGAAAGAAGACTCCGAGAAGCTATTAGACAATGCTGGATAACCTGGACCGTACCTGTTGG  
A G A C G I P A A R V T K K E E L R E A I Q T M L D T P G P Y L L

1901 ATGTCATCTGTCCGCACCAAGAACATGTGTTACCGATGATCCCAAGTGGTGGCACTTTCGAAGATGTAATAACCGAAGGGGATGGTCGCACTAAGTACTG  
D V I C P H Q E H V L P M I P S G G T F E D V I T E G D G R T K Y

2001 AGAGATGAAGCTGGTGTATCATATGGTAAAAGACTTAGTTTTAGTTTTACAGTTTTCTTTGTGTGGTAATTTGGGTTTGTGAGTTGTTGTTCTGCTTT

2101 TGGTTTGTCCCKWAC

**FIG. 1D**



List of oligonucleotides suitable for detection of the PM1 and PM2 mutations. All oligonucleotides are in 5'-3' orientation.

SEQ ID NO.	AHAS1-PM1 forward	SEQ ID NO.	AHAS1-PM1 reverse	SEQ ID NO.	AHAS3-PM2 forward	SEQ ID NO.	AHAS3-PM2 reverse
5	TTATCTCGGGACCCGGCAA	24	CATCTTTGAAAAGTGCCACCA	47	CTCAGGACTCGGAGCTATGG	66	CTTTGTAGAACCAGATCTTCC
6	GACCCGGCAAGGAGAACGA	25	TCTGTTATTACATCTTTGAA	48	GGAGCTATGGGTTTCGGACT	67	GCTCTGTAGCTTGTAGAA
7	GGGAGAACGAGATCTTCCCT	26	ACCATCCCTTCTGTATTATA	49	GTTTCGGACTTCCCTGCTGCG	68	AFAAGTGTGAGCTCTGTAG
8	GATCTTCCCTAACATGCTGC	27	ACTTAGTGGACCATCCCT	50	TCCTGCTCGGATTGGAGCGT	69	GGTCCCGAGATAAGTGTGA
9	AACATGCTGCAGTTTGCAGG	28	ATCTCTCAGTACTTAGTGCG	51	ATTGGAGCTCTGTGGCGAA	70	TCCCTTGCCTGGTCCCCGGAG
10	AGTTTGCAGGAGCTTGGGG	29	CACCAGCTTCACTCTCAGT	52	CTGTGGCGAACCCCTGATGCG	71	GATCTCGTTCTCCCTTGGCCG
11	AGCTTGGGGATTCCAGCTG	30	TATGATCGATCACCAGCTTC	53	CCCTGATCGGATTGTGTGG	72	TGTTAGGGGAAGATCTCGTTC
12	ATTCCAGCTGCGAGAGTGAC	31	TCCTTTACCATATGATCGAT	54	ATTGTTGTGGACATTGACGG	73	AACTGCAGCATGTTAGGGAA
13	CGAGAGTGACGAAGAAGAA	32	TGAAACTAAGTCTTTTACCA	55	ACATTGACGGTGTGGAAGC	74	AGCTCCTGCAAAACTGCAGCA
14	GAAGAAAGAAGAACTCCGAG	33	AACTGGAAACTGAAAATAAG	56	TGATGGAAAGCTTCAATAATGA	75	GAATCCCGCAAGCTCCTGCA
15	GAATCCGAGAGCTATTCA	34	ACACAAAAGAAACTGGAAAC	57	TTCATAAATGAACGTTCAAGA	76	CTCGCAGCTGGAATCCCGCA
16	AAGCTATTGAGACAATGCTG	35	CCAAATTACCACACAAAAGA	58	ACGTTCAAGAGCTGGCCACA	77	CTTCCGTCACCTCTCGCAGCTG
17	GACAATGCTGGATACACCAG	36	ACTGACAAAACCCAAATTACC	59	GCTGGCCACAATCCCTGTAG	78	GTTTCTCTTCTTCTTCTGCTACT
18	GATACACCAGGACCATACCT	37	TAGTACAACAACCTGACAAAAC	60	ATCCGTGTAGAGAAATCTTCC	79	GCTTCTCGGAGTCTTCTTTT
19	GACCATACCTGTTGGATGTG	38	CAACCAAAAAGTAGTACAACA	61	AGAAATCTTCTGTGAAGATA	80	TGCTCTGAATAGCTTCTCGGA
20	GTTGGATGTGATATGTCCGC	39	CGTCTGGGAACAACCAAAAAG	62	TGTGAAGATACTCTTGTAA	81	TATCCAGCATTTGTCTGAATA
21	ATATGTCGGACCAAGAACA	40	ACAGCGAGTACGTTCTGGAA	63	CTCTTGTAAACAACCCAGCA	82	GGTCCAGGTGTATCCAGCAT
22	ACCAAGAACAATGTTTACCG	41	CAAAAACAACAACAGCGAGTA	64	ACAACCCAGCATCTTGGGATG	83	CAACAGGTACGGTCCAGGTG
23	TGTGTTACCGATGATCCCAA	42	AAAAAGGAAAACAACAACAACA	65	TCTTGGGATGGTCAATGCAAT	84	AGATGACATCCAACAGGTAC
43	ATGATCCCAAGTGGTGGCACT	44	AGTGCCACCACCTTGGGATCAT	85	GTCATGCAATGGGAAGATCCGG	86	CCGATCTTCCCATTTGCATGAC
45	ATGATCCCAAAATGGTGGCACT	46	AGTGCCACCACCTTGGGATCAT	87	GTCATGCAATTTGGGAAGATCCGG	88	CCGATCTTCCCAATTTGCATGAC


All oligonucleotides noted as being in the forward direction are located on the 5' side of either PM1 or PM2 mutation, in reference to SEQ ID:1 and SEQ ID:2. All oligonucleotides noted as being in the reverse direction are located on the 3' side of either the PM1 or PM2 mutation, in reference to SEQ ID:3 and SEQ ID:4.

FIG. 1E


# “PM1” Test

## AHAS1

‘Topas’



‘PM1’



## FIG. 2



Doubled Haploid Canola Lines		
Plant number	class	GH Rating
1	"PM1/PM2"	0
2	"PM1/PM2"	0
3	"PM1/PM2"	0
4	"PM1/PM2"	0
6	"PM1/PM2"	5
7	"PM1/PM2"	5
37	"PM2"	20
38	"PM2"	20
39	"PM2"	20
40	"PM2"	25
41	"PM2"	25
42	"PM2"	25
68	"PM1"	40
69	"PM1"	40
70	"PM1"	40
71	"PM1"	40
72	"PM1"	40
73	"PM1"	45
103	WT	80
104	WT	80
105	WT	80
106	WT	80
107	WT	85
108	WT	85
-	"PM1"	-
-	"PM2"	-
-	W T	-

**FIG. 4**

Summary of results from "PM1" and "PM2" mutation tests with three replicates using the ABI PRISM Technology

DNA class	Plant number <sup>2</sup>	"PM1" mutation test		"PM2" mutation test			
		Observed <sup>3</sup>	Expected <sup>4</sup>	Observed <sup>3</sup>	Expected <sup>4</sup>		
"PM1/PM2" class	1	(C)-T	C-T	(C)-A	C-A	yes	yes
	2	(C)-T	C-T	(C)-A	C-A	yes	yes
	3	(C)-T	C-T	(C)-A	C-A	yes	yes
	4	(C)-T	C-T	(C)-A	C-A	yes	yes
	6	(C)-T	C-T	(C)-A	C-A	yes	yes
	7	(C)-T	C-T	(C)-A	C-A	yes	yes
	37	(C)-T	C	(C)-A	C-A	yes	yes
"PM2" class	38	(C)-T	C	C-A	C-A	yes	yes
	39	(C)-T-(A)	C	(C)-A	C-A	yes	yes
	40	C	C	(C)-A	C-A	no	yes
	41	(C)-T	C	(C)-A	C-A	yes	yes/no
	42	(C)-T	C	(C)-A	C-A	yes	yes
	68	T	C-T	C	C	yes	no
"PM1" class	69	T	C-T	C	C	yes	no
	70	T	C-T	C	C	yes	no
	71	T	C-T	C	C	yes	no
	72	T	C-T	C	C	yes	no
	73	T	C-T	C	C	yes	no
	103	C	C	C	C	no	no
"WT" class	104	C	C	C	C	no	no
	105	C	C	C	C	no	no
	106	C	C	C	C	no	no
	107	C	C	C	C	no	no
	108	C	C	C	C	no	no
	-	(C)-T	C-T	C	C	yes	no
"PM1" control <sup>1</sup>	-	C	C	C-A	C-A	yes	yes
"PM2" control <sup>1</sup>	-	C	C	C	C	no	no
"Topas" (WT) control <sup>1</sup>	-	C	C	C	C	no	no

<sup>1</sup>'PM1' control and 'PM2' control are DNA isolated from "PM1" and "PM2" plants used to develop the tests.

<sup>2</sup>This number refers to the plant number for DH line identified in Figure 4

<sup>3</sup>In **Bold** and *italics* are the peaks related to the mutations and in brackets are the peaks that are not always present in all the three replicates.

<sup>4</sup>Expected results assuming that the AHAS amplification on reaction using AHAS1/AHAS3 amplification primers (S ED ID NO:90 and 91) amplified similar amounts of both AHAS1 and AHAS3 sequences and that the PM1 extension primers will anneal also to the AHAS3 sequence and the PM2 extension primers will anneal also to the AHAS1 sequence.

FIG. 5

Summary of results from "PM1" and "PM2" mutation tests using the Pyrosequencing PSQ 96 Technology

DNA sample	"PM1" mutation test			"PM2" mutation test		
	Pyrosequencing results	SEQ ID NO	"PM1" Mutation	Pyrosequencing results	SEQ ID NO	"PM2" Mutation
'PM1'	CAAATGGTGG	98	Yes	GGGAAGATC	99	No
'PM2'	CAAGTGGTGG	97	No	TGGGAAGATC	100	Yes
'Topas' (WT)	CAAGTGGTGG	97	No	GGGAAGATC	99	No

FIG. 6